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Abstract
Introduction:	This	document	presents	the	guidelines	of	the	Polish	Respiratory	Society	(PTChP,	Polskie Towarzystwo Chorób Płuc)	
for	diagnosis	and	treatment	of	idiopathic	pulmonary	fibrosis	(IPF),	developed	by	a group	of	Polish	experts.
Material and methods:	The	recommendations	were	developed	in	the	form	of	answers	to	previously	formulated	questions	concer-
ning	everyday	diagnostic	and	therapeutic	challenges.	They	were	developed	based	on	a current	literature	review	using	the	Grading	
of	Recommendations	Assessment,	Development	and	Evaluation	(GRADE)	methodology.
Results:	We	formulated	28	recommendations	for	diagnosis	(8),	pharmacological	treatment	(12)	as	well	as	non-pharma-
cological	and	palliative	 therapy	 (8).	The	experts	suggest	 that	surgical	 lung	biopsy	 (SLB)	not	be	performed	 in	patients	
with	the	probable	usual	interstitial	pneumonia	(UIP)	pattern,	with	an	appropriate	clinical	context	and	unanimous	opinion	
of	 a  multidisciplinary	 team.	 The	 experts	 recommend	 using	 antifibrotic	 agents	 in	 IPF	 patients	 and	 suggest	 their	 use	
irrespective	of	the	degree	of	functional	impairment.	As	regards	non-pharmacological	and	palliative	treatment,	strong	re-
commendations	were	formulated	regarding	pulmonary	rehabilitation,	oxygen	therapy	(in	patients	with	chronic	respiratory	
failure),	preventive	vaccinations	as	well	as	referring	IPF	patients	to	transplant	centres.	Table	1	presents	an	aggregate	list	
of	recommendations.
Conclusions:	The	Polish	Respiratory	Society	Working	Group	developed	guidelines	for	IPF	diagnosis	and	treatment.
Key words: diagnosis,	idiopathic	pulmonary	fibrosis,	treatment,	differentiation,	usual	interstitial	pneumonia
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Table 1. An aggregate list of recommendations 
Module No Question Recommendation
Diagnosis 1 Can	IPF	be	diagnosed	without	lung	biopsy	in	a pa-
tient	with	“probable	UIP”	HRCT	pattern	(without	
honeycombing,	but	with	peripheral	traction	bron-
chiectasis	or	bronchiolectasis)?
We	suggest	that	a “probable	UIP”	HRCT	pattern,	if	it	contains	no	
changes	suggestive	of	an	alternative	diagnosis,	in	an	appropriate	
clinical	context	(e.g.	male	sex,	smoking	history,	age	>	60)	and	
after	excluding	other	causes	of	such	changes,	should	be	a suffi-
cient	basis	for	a multidisciplinary	team	to	diagnose	IPF	with	no	
need	for	diagnostic	lung	biopsy
2 Can	a UIP	pattern	confirmed	by	pathomorphologi-
cal	examination	of	material	collected	through	cry-
obiopsy	be	considered	equivalent	to	a diagnosis	
made	based	on	surgical	biopsy?
We	suggest	that	material	collected	for	pathomorphological	exa-
mination	through	cryobiopsy,	sufficient	to	diagnose	UIP,	should	
be	considered	equivalent	to	material	from	surgical	lung	biopsy
3 What	respiratory	function	examinations	should	
be	performed	to	assess	the	risk	of	lung	biopsy	
complications?
We	recommend	that	qualification	for	elective	lung	biopsy	include	
arterial	blood	gas	analysis,	spirometry	and	assessment	of	trans-
fer	factor	for	carbon	monoxide
4 Is	it	necessary	to	perform	serological	tests	for	
autoimmune	diseases	in	every	patient	with	su-
spected	IPF	without	clinical	signs	of	connective	
tissue	disease?
We	recommend	that	every	patient	with	suspected	IPF	undergo	
serological	tests	for	autoimmune	diseases
5 Is	it	necessary	to	determine	serum	concentrations	
of	specific	immunoglobulins	(precipitins)	in	order	
to	diagnose	hypersensitivity	pneumonitis	(allergic	
alveolitis)	in	every	patient	with	suspected	IPF?
We	recommend	that	a test	for	the	presence	of	specific	immu-
noglobulins	in	the	serum	(precipitins)	NOT	be	performed	in	all	
patients	with	suspected	IPF
6 Should	BAL	be	performed	in	every	patient	with	
suspected	IPF?
We	suggest	that	BAL	NOT	be	performed	in	every	patient	with	
suspected	IPF.
The	examination	is	not	necessary	in	patients	with	a radiographic	
UIP	pattern	if	the	clinical	context	raises	no	doubt,	but	it	can	be	
helpful	in	differential	diagnosis	of	ambiguous	clinical	or	radio-
graphic	picture	
7 What	is	the	role	of	a multidisciplinary	team	in	
diagnosing	IPF	and	who	should	be	part	of	such	
a team?
We	recommend	establishing	the	diagnosis	in	all	patients	diagno-
sed	with	signs	of	fibrosis	due	to	ILD	through	a multidisciplinary	
discussion
We	recommend	that	a multidisciplinary	team	include	at	least	
a clinician	(pulmonologist)	and	radiologist	as	well	as	pathologist	
(if	lung	biopsy	has	been	performed).	All	team	members	should	
be	experienced	in	the	diagnosis	of	ILD
8 How	to	define	disease	progression? We	suggest	that	FVC	decline	rate	be	recognized	as	the	basic	me-
asure	of	IPF	progression.	A loss	≥ 10%	of	predicted	value	within	
12 months	or	less	is	considered	clinically	relevant
Pharma-
cological	
treatment
9 Should	IPF	patients	be	treated	with	pirfenidone? We	recommend	the	use	of	pirfenidone	in	IPF	patients
10 Should	IPF	patients	be	treated	with	nintedanib? We	recommend	the	use	of	nintedanib	in	IPF	patients
11 Can	IPF	patients	be	treated	simultaneously	with	
pirfenidone	and	nintedanib?
Currently,	we	DO	NOT	recommend	simultaneous	use	of	pirfenido-
ne	and	nintedanib	in	IPF	patients
12 Should	patients	diagnosed	with	IPF	based	on	the	
clinical	context	and	the	“probable	UIP”	pattern	in	
lung	HRCT	be	treated	with	antifibrotic	agents?	
We	suggest	that	patients	with	IPF	diagnosis	established	by	a mul-
tidisciplinary	team	based	on	the	clinical	context	and	the	“probable	
UIP”	pattern	in	lung	HRCT	be	started	on	antifibrotic	agents
13 Should	IPF	patients	with	mildly	decreased	or	
normal	pulmonary	function	parameters	be	treated	
with	antifibrotic	agents?	
We	suggest	that	antifibrotic	treatment	be	proposed	to	IPF	
patients	with	mildly	decreased	or	normal	pulmonary	function	
parameters
Æ
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Module No Question Recommendation
Pharma-
cological	
treatment
14 Should	IPF	patients	with	severe	lung	function	im-
pairment	(FVC	< 50%	of	predicted,	TL,CO	< 30%	of	
predicted)	be	treated	with	antifibrotic	agents?
We	suggest	that	antifibrotic	treatment	following	IPF	diagnosis	be	
proposed	to	all	patients	without	contraindications	for	this	treat-
ment,	irrespective	of	the	degree	of	lung	function	impairment
15	 Is	disease	progression	an	indication	for	discontinu-
ation	of	antifibrotic	treatment?
We	suggest	that	disease	progression	NOT	be	an	indication	for	
discontinuation	of	antifibrotic	treatment
16 In	what	situations	should	one	consider	switching	
from	one	antifibrotic	agent	to	the	other?
We	suggest	switching	from	one	antifibrotic	agent	to	the	other	in	
case	of	significant	lack	of	tolerance	or	adverse	effects
17 Should	all	IPF	patients	be	treated	with	anti-acid	
agents?
We	suggest	that	anti-acid	agents	in	IPF	patients	NOT	be	used	in	
absence	of	other	indications	for	such	treatment
18	 Should	N-acetylcysteine	be	used	in	IPF	treatment?	 We	recommend	that	N-acetylcysteine	NOT	be	used	in	the	treat-
ment	of	IPF	patients,	either	as	monotherapy	or	in	combination	
with	other	agents.
19 Should	IPF	patients	receive	immunosuppressive	
treatment?
We	recommend	that	NO	type	of	immunosuppressive	treatment	
be	used	in	IPF	patients
20 Should	agents	dedicated	to	treating	pulmonary	
hypertension	be	used	in	IPF	patients?
We	suggest	that	agents	dedicated	to	treating	pulmonary	hyper-
tension	NOT	be	used	in	IPF	patients
Non-pharma-
cological		
and	palliative	
treatment
21 Should	pulmonary	rehabilitation	be	used	in	IPF	
patients?
We	recommend	the	use	of	pulmonary	rehabilitation	in	IPF	pa-
tients
22 Should	LTOT	be	used	in	patients	with	respiratory	
failure	in	the	course	of	IPF?
We	recommend	using	LTOT	in	patients	with	chronic	respiratory	
failure	in	the	course	of	IPF
23 Should	oxygen	be	used	during	exercise	in	IPF	
patients?
We	suggest	using	oxygen	during	exercise	in	IPF	patients	with	
dyspnoea	and	exertional	desaturation
24 Should	preventive	vaccinations	be	used	in	IPF	
patients?
We	recommend	use	of	pneumococcal	and	flu	vaccinations	in	IPF	
patients
25 Should	patients	with	advanced	IPF	be	referred	to	
palliative	care	centres?	
We	suggest	that	patients	with	advanced	IPF	be	referred	to	pallia-
tive	care	centres
26 Should	morphine	be	used	in	palliative	treatment? We	suggest	using	oral	morphine	in	patients	with	severe	IPF	in	
palliative	treatment	of	persisting	dyspnoe
27 Should	invasive	ventilation	be	used	in	IPF	patients	
with	acute	respiratory	failure?
We	suggest	that	invasive	ventilation	NOT	be	used	in	IPF	patients	
with	acute	respiratory	failure
28 Should	IPF	patients	be	referred	to	lung	transplant	
centres	and	if	so,	when?
We	recommend	referring	to	lung	transplant	centres	all	IPF	pa-
tients	without	contraindications	for	the	procedure
We	suggest	referring	IPF	patients	to	lung	transplant	centres	im-
mediately	after	the	disease	is	diagnosed
BAL	—	bronchoalveoar	lavage;	FVC	—	forced	vital	capacity;	HRCT	—	high-resolution	computed	tomography;	IPF	—	idiopathic	pulmonary	fibrosis;	ILD	—	interstitial	
lung	disease;	LTOT	—	long-therm	oxygen	therapy;	TL,CO	—	transfer	factor	of	the	lung	for	carbon	monoxide;	UIP	—	usual	interstitial	pneumonia
Table 1 cont. An aggregate list of recommendations
INTRODUCTION
Definition, epidemiology, aetiopathogenesis
Idiopathic pulmonary fibrosis (IPF) is a chronic 
interstitial lung disease (ILD) limited to the lungs, 
associated with progressive fibrosis and consequen-
tially with disturbances in diffusion of respiratory 
gases through the alveolar-capillary membrane, 
most commonly restrictive ventilation impairment, 
respiratory failure and premature death. The dis-
ease affects the elderly, more frequently males, and 
individuals with a history of tobacco smoking.
The aetiology is unknown and the diagnosis 
is conditional upon identifying the so-called ra-
diographic or histopathological pattern of usual 
interstitial pneumonia (UIP) in a patient in whom 
other causes of ILD have been excluded, such as 
extrinsic factors damaging the respiratory system 
or comorbidities that could be associated with 
lung changes of a similar nature.
Idiopathic pulmonary fibrosis belongs to 
a group of diseases called idiopathic interstitial 
pneumonias (IIP) and is the most frequent con-
dition in this group (accounting for 50–60% 
of IIP cases) [1]. It is one of the most common 
interstitial diseases, accounting for 20% of all 
diagnoses in patients diagnosed and treated in 
reference centres [2]. The disease is rare (affec-
ting < 50 patients per a population of 100, 000). 
Its incidence, based on data from New Mexico 
(US), is estimated at 10.7 per 100, 000/year for 
men and 7.4 per 100, 000/year for women [3]. 
British data suggest an incidence of 4.6 per 100, 
Advances in Respiratory Medicine 2020, vol. 88, no. 1, pages 42–95
46 www.journals.viamedica.pl
000/year in the general population [4]. Prevalen-
ce based on data from an American registry of 
medical services from 1996–2000 is estimated at 
14–47 per 100, 000 [5]. In Poland, no systematic 
epidemiological studies of IPF have been perfor-
med. Szafrański [6] estimated the incidence of 
interstitial lung disease at 5.0 per 100, 000/year 
when coded as J84 and at 2.5 per 100, 000/year 
when coded as J84.1. He compiled this data based 
on an admission registry of one of non-academic 
lung disease centres which admitted 554 patients 
with interstitial diseases in 2000–2009. Of those 
patients, 55.7% were individuals with a diagnosis 
coded as J84. In a publication called the Polish 
IPF White Book (Polska Biała Księga IPF) [7], 
the calculations of the estimated number of IPF 
patients in Poland were based on mean values 
from different countries: for incidence it was 4.7 
and for prevalence 17.1 per 100, 000. This way, 
the number of patients diagnosed with IPF was 
estimated at 6585 and the number of annual new 
cases at 1809. However, one should remember 
that the accuracy of disease coding around the 
world is low, and imprecise diagnostic criteria 
can render an especially significant bias in co-
ding. Another problem may be introduced by 
non-specific symptoms, which result in the time 
from onset to diagnosis of up to several years 
and misdiagnosis of many IPF patients [8]. Fur-
thermore, the reliability of epidemiological data 
is undoubtedly affected by the fact that the first 
systematic criteria for IPF were published only 
in 2000 [9] and radically redefined in 2011 [10], 
while most of the cited epidemiological data come 
from before these publications. The authors of the 
epidemiological report from the United Kingdom 
point to an increase in incidence observed in re-
cent years [4]. Szafrański also suggests a possible 
upward trend [6].
Age, the male sex and tobacco smoking are 
named as risk factors for IPF. Studies examine 
the effects of chronic, mostly viral infections 
(among others, Epstein-Barr virus, other Herpes 
viruses, hepatitis C), although their role in aetio-
pathogenesis remains controversial [11–15]. The 
relationship between IPF and gastroesophageal 
reflux (GER) is also unclear. The latter promotes 
microaspirations of gastric content into the re-
spiratory system and can potentially be a factor 
directly injuring the alveolar epithelium. We 
still lack an answer to the question whether this 
phenomenon causes the disease process or rather 
is a consequence of pulmonary fibrosis, which 
is associated with changes in the anatomy and 
pressure distribution within the chest, promoting 
regurgitation of the gastrointestinal content [16, 
17]. Not without significance is the impact of 
genetic factors [18]. Mutations within the telo-
merase complex genes and genes encoding sur-
factant proteins C and A2 as well as MUC5B gene 
polymorphism are known to increase the risk of 
pulmonary fibrosis [19, 20]. Mutations promoting 
the development of the disease are more frequ-
ent in familial interstitial pneumonia (FIP) [21]. 
Findings of UIP features can be an element of the 
rare Hermansky-Pudlak syndrome, an autosomal 
recessive hereditary disease, in which lung chan-
ges are additionally accompanied by such features 
as oculocutaneous albinism and platelet function 
disorders caused by lack of delta granules [22].
In light of the current studies, IPF is a con-
sequence of repeated microinjuries of the alveolar 
epithelium caused by factors such as tobacco 
smoke components, environmental pollutants, 
viruses, occupational factors or gastric content 
microaspirations. The development of fibrosis is 
conditional upon alveolar epithelial dysfunction 
(acquired or genetically determined), making the 
epithelium incapable of physiological regenera-
tion [23]. Cell-level abnormalities are known as 
“accelerated ageing” or “cellular senescence”. 
Features indicative of this process include, among 
others, shortened telomeres. In IPF patients, both 
with the sporadic and familial forms, shorter te-
lomeres have been identified in peripheral blood 
lymphocytes and alveolar epithelial cells [24–26], 
and shorter telomere length in IPF patients is cor-
related with shorter life spans [25, 27]. Another 
important phenomenon observed in epithelial 
cells is intracellular accumulation of abnormal 
proteins (unfolded protein response), associated 
with impairment of the autophagy process. These 
phenomena lead to an endoplasmic reticulum 
[ER] stress response and in consequence to the ac-
tivation of proapoptotic signals and shortening of 
the epithelial cells’ lives [28]. Fibrosis requires an 
appropriate environment to develop, one which 
depends on cell-secreted cytokines. The main role 
is played here by growth factors i.e. transforming 
growth factor-ß, TGF-ß; fibroblastic growth factor, 
FGF; platelet-derived growth factor, PDGF; vascu-
lar endothelial growth factor, VEGF; connective 
tissue growth factor, CTGF; and cytokines e.g. 
interleukin (IL)-1, IL-4, IL-13. This results in the 
deposition of collagen and other components of 
extracellular matrix produced directly by stimu-
lated fibroblasts (myofibroblasts). The accumu-
lation of these substances in lungs is a result of 
epithelial-mesenchymal transition (EMT) during 
which epithelial cells undergo morphological 
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Figure 1. Selected	mechanisms	leading	to	pulmonary	fibrosis	in	IPF	(author:	AJB)
CCL	—	chemokine	(C-C	motif)	ligand;	CXCL	C-X-C	motif	chemokine	ligand;	CTGF	—	connective	tissue	growth	factor;	FGF	—	fibroblastic	growth	factor;	
LPC	—	lysophosphatidylcholine;	PDGF	—	platelet-derived	growth	factor;	TGF	—	transforming	growth	factor;	VEGF	—	vascular	endothelial	growth	factor
and functional transformation into mesenchymal 
cells. Another source of fibroblasts in lungs are 
fibrocytes, cells originating from bone marrow, 
which acquire mesenchymal features after they 
are released to the blood stream. When they 
reach the lungs, they transform into fibroblasts, 
and then myofibroblasts. Selected mechanisms 
leading to pulmonary fibrosis in IPF are sum-
marised in Figure 1.
The radiographic pattern of usual interstitial 
pneumonia (UIP)
UIP pattern
The definition of the UIP pattern in high-res-
olution computed tomography (HRCT) includes 
reticulation with a predominantly subpleural 
(occasionally diffuse) and basal distribution. 
Changes of crucial importance for UIP diagnosis 
by CT are those of “honeycombing”, with or with-
out peripheral bronchiectasis or bronchiolectasis, 
without findings indicative for alternative diagno-
ses (Table 2). Honeycomb-type changes manifest 
as clusters of well-defined, thick-walled, usually 
subpleural, cyst-like air spaces with a diameter of 
several millimetres to several centimetres (usually 
3–10 mm) [10, 29] (Figure 2).
Bronchiectasis or bronchiolectasis are pe-
ripherally located in the areas of reticulation 
(traction bronchiectasis). A characteristic feature 
for UIP is heterogeneity of lesions, meaning that 
areas with architectural distortion are found next 
to areas of relatively normal parenchymal struc-
ture. The UIP pattern is characteristic of IPF but 
can also be present in other disease entities. After 
known causes of UIP are excluded, it is possible to 
diagnose IPF without invasive approach [10, 29]. 
The probable UIP pattern
Lack of honeycombing in the HRCT image, 
with the presence of reticular changes predom-
inantly in the subpleural and basal lung areas, 
Advances in Respiratory Medicine 2020, vol. 88, no. 1, pages 42–95
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Table 2.  Criteria for identifying a UIP pattern based on high-resolution computed tomography (Adapted from [29], with modifications)
UIP Probable UIP Indeterminate Findings suggestive of a different  
diagnosis
Subpleural	and	basal	predomi-
nant
The	distribution	is	often	hetero-
geneous,	in	many	cases	asym-
metrical
Honeycombing	with	or	without	
peripheral	traction	bronchiecta-
sis	or	bronchiolectasis
Reticular	changes
Possible	presence	of	mild	ground	
glass	opacifications	as	well	as	
isolated	calcified	nodules	(ossifi-
cations)	in	fibrotic	areas
Subpleural	and	basal	pre-
dominant
The	distribution	is	often	
heterogeneous,	in	many	
cases	asymmetrical
No	honeycombing
Reticular	changes	with	pe-
ripheral	traction	bronchiec-
tasis	or	bronchiolectasis
Possible	presence	of	mild	
ground	glass	opacifications
Subpleural	and	basal	pre-
dominant
Subtle	reticulation,	possible	
presence	of	mild	ground	
glass	opacifications	and	
architectural	distortion	(the	
“early	UIP”	pattern)
CT	features	of	interstitial	
fibrosis	or	the	nature	or	
distribution	of	changes	not	
suggestive	of	any	specific	
aetiology	(truly	indetermi-
nate)
Cysts
Marked	mosaic	attenuation
Prevalence	of	ground	glass
Profuse	micronodules
Centrilobular	nodules
Other	nodules
Consolidation
Peribronchovascular,	perilymphatic	distribution	
Changes	in	the	upper	or	mid-lung	fields
Pleural	plaques
Dilated	oesophagus
Distal	clavicular	erosions
Extensive	lymph	node	enlargement
Pleural	effusion,	pleural	thickening
UIP	—	usual	interstitial	pneumonia; CT	—	computed	tomography
Figure 2. High-resolution	computed	tomography	images	depicting:	A and	B	—	usual	interstitial	pneumonia;	C	and	D	—	usual	interstitial	pneumonia	
concomitant	to	emphysema	(from	Radiology	Department,	N.	Barlicki	University	Teaching	Hospital	No	1 in	Lodz).	Honeycoming	located	subpleurally	
at	lung	bases	(blue	ovals),	traction	bronchiectasis	(blue	arrows),	concomitant	emphysema	(white	asterisks)
A B
C D
with peripheral traction bronchiectasis or bron-
chiolectasis warrants the diagnosis of probable 
UIP. Differentiation of bronchiectasis from honey-
combing can be difficult. Traction bronchiectasis 
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Figure 3.	High-resolution	computed	tomography	images	illustrating	the	probable	UIP	pattern	(from	the	Radiology	Department,	N.	Barlicki	Univer-
sity	Teaching	Hospital	No	1 in	Lodz).	A —	axial	view;	B	—	coronal	view.	Subpleural	reticulation	located	at	the	lung	bases	(blue	arrows),	traction	
peripheral	bronchiectases	(blue	oval)
A B
is irregular, deformed widening of bronchi and 
bronchioles caused by fibrosis of the surrounding 
lung parenchyma. Unlike bronchiectasis of dif-
ferent origin, it is located in the area of reticular 
changes and associated with signs of lobular 
destruction and architectural distortion of the 
lung parenchyma. A conglomerate of peripheral 
traction bronchiolectasis located in the basal 
lung parts can resemble a honeycombing. Fea-
tures differentiating traction bronchiectasis from 
honeycombing include: lack of bronchiectasis or 
bronchiolectasis directly below the pleura (hon-
eycomb cysts are usually located subpleurally) 
and distribution of cysts. In bronchiolectasis the 
cysts are separated from each other whereas in 
a honeycombing area they are close together and 
share walls [30, 31]. An example HRCT image 
illustrating probable UIP is presented in Figure 3.
Indeterminate pattern
An indeterminate pattern is one in which 
no honeycombing or traction bronchiectasis or 
bronchiolectasis is seen but at the same time no 
features are observed that would allow a  spe-
cific diagnosis. This category includes patients 
with slight, limited reticular changes, often with 
concomitant ground glass opacifications or archi-
tectural distortions distributed in subpleural and 
basal regions of the lung (the “early UIP” pattern). 
An example of such an HRCT image is presented 
in Figure 4. If the nature of lung changes distri-
bution does not suggest any specific aetiology, we 
call it a truly indeterminate pattern. Such patients 
should undergo supplementary HRCT examina-
tions in the prone position in order to discreetly 
differentiate early fibrosis from changes caused 
by the gravitational effect.
An indeterminate pattern does not preclude 
IPF diagnosis but requires pathomorphological 
examination to confirm the UIP pattern.
Pathomorphological UIP pattern
Morphological changes appearing in the 
course of IPF are identified in microscopic exa-
mination, similarly to radiographic examination, 
as UIP. The international ATS/ERS/JRS/ALAT 
recommendations (2018) [29] for diagnosis of 
IPF as well as recommendations contained in 
the Fleischner Society White Paper [31] point to 
benefits of making IPF diagnosis based on SLB, 
which remains the gold standard of microscopic 
diagnosis of IPF/UIP, in spite of growing expe-
rience with other material collection techniques, 
such as cryobiopsy.
Microscopic changes characteristic of UIP:
— intensive collagenous fibrosis, leading to 
remodelling of the lung parenchyma, with 
complete honeycomb-type destruction;
— disseminated fibroblastic foci, usually located 
at the periphery of remodelling areas;
— areas of fibrosis separated by fragments of less 
affected lung parenchyma (the characteristic 
mosaicism reflecting different times of change 
formation);
— changes located below the pleura, along the in-
terlobular septa, at the periphery of the lobules;
— lack of morphological changes indicative of 
alternative diagnosis (e.g. granulomas, organ-
ising pneumonia, diffuse alveolar damage) or 
fibrosis located in other areas than those char-
acteristic of UIP (e.g. around the bronchioles).
A microscopic image with signs of usual 
interstitial pneumonia is presented in Figure 5.
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Figure 4.	HRCT	images	illustrating	an	indeterminate	pattern.	The	radiographic	image	corresponds	to	the	early	UIP	pattern	(from	the	Division	of	
Imaging	Diagnostics,	Voivodeship	Hospital	in	Opole).	Axial	views:	A —	at	the	aortic	arch	level;	B	—	of	the	main	bronchi;	C	—	supradiaphragmatic;	
D	—	a magnified	fragment	of	the	middle	lobe.	Ground	glass	areas	(blue	ovals),	mild	reticular	thickening	of	septal	lines	(arrows)	which	are	predomi-
nant	in	the	subpleural	and	supradiaphragmatic	(basal)	areas.	Changes	are	also	visible	in	the	middle	lobe,	near	the	anterolateral	wall,	which	indicates	
they	are	not	associated	with	hydrostatic	effect.	Pathomorphological	examination	confirmed	UIP
A B
C D
Figure 5.	 Pathomorphological	 UIP	 patterns	 (Department	 of	 Pathology,	National	 Tuberculosis	 and	 Lung	Diseases	Research	 Institute,	Warsaw).	
A. A fragment	of	lung	parenchyma	with	visible	diffuse	fibrosis	affecting	the	subpleural	parenchyma,	interlobular	spaces,	with	a region	of	less	affec-
ted	lung	parenchyma.	Low	magnification;	B. A fragment	of	lung	parenchyma	with	diffuse	fibrosis,	with	a focus	of	fibroblastic	fibrosis	(fibroblastic	
focus)	visible	in	the	central	part	(arrow).	High	magnification;	C. Lung	parenchyma	with	areas	of	cystic	remodelling	of	air	spaces	with	creation	of	
honeycomb-type	areas.	Medium	magnification;	D. Fields	of	completed	fibrosis	distorting	the	lung	structure	are	separated	by	small	fragments	of	
aerial	parenchyma	(mosaicism).	Medium	magnification
C C
C C
A B
D
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Table 3. The histopathological criteria for UIP diagnosis (Adapted from [29]) 
Definite UIP Probable UIP Indeterminate Morphological changes indica-
tive of a different diagnosis
Dense	fibrosis	with	architectural	
distortion	of	the	lung	parenchy-
ma	and/or	honeycombing	
Some	features	described	in	
column	1	are	present,	but	to	an	
extent	that	precludes	a definite	
diagnosis	of	UIP/IPF
Fibrosis	with	or	without	architec-
tural	distortion	of	the	parenchy-
ma	with	morphological	features	
suggestive	of	a different	diagno-
sis	than	UIP,	or	with	features	
indicative	of	secondary	UIP	asso-
ciated	with	a different	cause*
Features	typical	of	other	inter-
stitial	fibrosis	types	(e.g.	absent	
fibroblastic	foci,	loose	connec-
tive	tissue	fibrosis	covering	
the	entire	area	of	the	examined	
specimen)
—	 Predominant	subpleural	and/
or	paraseptal	distribution	of	
fibrosis
—	 Patchy	involvement	of	lung	
parenchyma	by	fibrosis
—	 Fibroblastic	foci
—	 Absence	of	morphological	
features	suggestive	of	an	
alternate	diagnosis	
—	 Absence	of	morphological	
features	suggestive	of	an	
alternative	diagnosis	or
—	 Presence	of	honeycombing	
only	
Certain	changes	present	in	co-
lumn	1	are	present	but	with	mor-
phological	features	suggestive	of	
an	alternative	diagnosis**	
Morphological	changes	indi-
cative	of	a different	diagnosis	
(e.g.	HP,	LAM,	Langerhans	cell	
histiocytosis)
*Granulomas,	hyaline	membranes	(except	for	acute	exacerbation	of	IPF),	pronounced	peribronchiolar	location,	diffuse	areas	of	intensive	inflammatory	infiltration	in	the	
stroma	without	fibrosis,	intensive	chronic	fibrosis	of	the	pleura,	organising	pneumonia
**Diffuse	inflammatory	infiltration	in	areas	away	from	remodelling	fields,	intensive	hyperplasia	of	lymphoid	tissue	with	the	presence	of	lymph	nodules	and	germinal	
centres,	peribronchiolar	location	with	peribronchiolar	metaplasia	(bronchiolisation)
HP	—	hypersensitivity	pneumonitis;	IPF	—	idiopathic	pulmonary	fibrosis;	LAM	—	lymphangioleiomyomatosis;	UIP	—usual	interstitial	pneumonia
Microscopic diagnosis requires not only 
an experienced pathologist, but also adequate 
fixation and preparation of material for pa-
thomorphological examination. The collected 
material should be fixed in a  10% solution 
of neutral buffered formalin. Lung fragments 
collected during SLB should be decompressed 
by injecting the lung parenchyma with a 10% 
formalin solution and placed in a vessel conta-
ining 10 times more fixing solution in relation 
to the specimen size.
The histopathological criteria for UIP diagno-
sis are presented in Table 3.
Microscopic diagnosis of UIP/IPF requires 
multidisciplinary cooperation. The pathologist 
must have access to detailed clinical data, infor-
mation on previous treatment and an up-to-date 
chest HRCT report. Referral for microscopic exa-
mination is completed by a clinician. 
Clinical picture
The most typical and common symptoms of 
this progressive disease include dyspnoea and 
non-productive, tiring cough. The symptoms 
usually appear insidiously, and many patients are 
unable to pinpoint the date of their appearance. 
Very often, deteriorating exercise tolerance fails 
to alarm patients at early stages as they explain 
the symptoms by the ageing or treat them as 
a consequence of long-term tobacco smoking. 
Other, less common and non-specific, complaints 
which are usually present in addition to exertio-
nal dyspnoea include general fatigue, dizziness, 
chest discomfort or pain and anxiety [32]. An 
acute exacerbation is a rare first manifestation of 
the disease. In such a case, the symptoms appear 
unexpectedly and intensify in a short time [33].
Most frequently, a patient diagnosed with IPF 
is male (approximately 70% of patients), a  for-
mer or, less frequently, current tobacco smoker 
(50–70% of patients), aged above 60 years [32, 
34]. In very rare case the diagnosis is made in 
patients under the age of 50. In 2–20% of patients 
the disease runs in the family. If this is the case, 
the first symptoms can develop even before the 
age of 40 [21, 35, 36].
Bilateral, basal crepitations (so called “Vel-
cro-type” cracles) identified during physical 
examination, especially with concomitant di-
gital clubbing, increases the likelihood of the 
diagnosis [32, 37]. Crepitations, although not 
pathognomonic, are present in about 90% of IPF 
patients. Digital clubbing is observed in < 30% 
of patients [32].
The clinical symptoms accompanying IPF 
are not characteristic of this condition only. 
Therefore, the condition is often misdiagnosed as 
another dyspnoea-associated disease (e.g. chronic 
obstructive pulmonary disease — due to tobacco 
smoking history) or heart failure (due to the pre-
sence of auscultatory crepitations in the lower 
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Table 4A. The GAP score, used to assess the risk of death 
Category Characteristic Number 
of points 
G	— gender Female	 0
Male	 1	
A —	age ≤ 60 0
61–65 1
> 65	 2	
P	—	physiology	(functio-
nal	examinations	—	FVC,	
TL,CO	in	reference	to	pre-
dicted	normal	values)
FVC	> 75% 0
FVC	50–75% 1
FVC	< 50% 2
TL,CO	> 55% 0
TL,CO	30–55% 1
TL,CO	< 30%	 2	
FVC	—	 foced	 vital	 capacity;	 TL,CO	—	 transfer	 factor	 of	 the	 lung	 for	 carbon	
monoxide
Table 4B. The table presents how the GAP score should be interpreted, with estimated risk of death in 3 consecutive 
years [57] 
Number of points Grade
GAP 
Mortality at 1 year [%] Mortality at 2 years [%] Mortality at 3 years [%] 
0–3	 I  5.6	 10.9	 16.3	
4–5	 II	 16.2	 29.9	 42.1	
6–8	 III	 39.2	 62.1	 76.8	
lung fields). In one study the mean time from 
the first symptoms to diagnosis was assessed at 
3–4 years. At least 50% of patients are previously 
diagnosed with COPD, asthma, other interstitial 
disease or heart failure. At least 50% of patients 
consult 3 or more specialists before receiving the 
correct diagnosis [8].
IPF is a  progressive disease. Progression 
pattern can be various, from slow loss of lung 
function parameters slightly above the loss 
associated with natural ageing, in which cases 
survival often exceeds 10 years, to violent pro-
gression leading to death sometimes in under 
1 year. Additionally, the disease course can be 
complicated with an acute exacerbation. Accor-
ding to a new definition [38], an acute exacer-
bation of IPF (AE-IPF) is a deterioration of the 
patient’s general condition with developing or 
worsening of dyspnoea, typically intensifying 
in a  period shorter than 30  days, associated 
with the appearance of new parenchymal con-
solidations or areas of ground glass overlapping 
existing sings of fibrosis characteristic of the UIP 
pattern. In most patients the cause of AE-IPF is 
never discovered. In others, the symptoms can 
result from known triggers, such as infection, 
air pollution, microaspirations or drugs. These 
events are associated with high mortality (early 
mortality of around 50%, exceeding 90% in in-
tubated and mechanically ventilated patients). 
Those who survive such an episode experience 
a chronic, irreversible worsening of lung func-
tion. The risk of AE-IPF is higher in patients with 
more advanced disease and lower baseline lung 
function parameters [38].
The clinical picture of IPF also involves co-
morbidities. Conditions which are more frequent 
in IPF patients than in the general population 
include gastroesophageal reflux disease (GERD) 
[39–41], lung cancer [42, 43], emphysema [42, 
44], pulmonary hypertension [38, 45, 46] and 
obstructive sleep apnoea [47]. Other common 
diseases characteristic of this age group include 
hypertension, ischaemic heart disease, car-
diac arrhythmias, stroke, other forms of arterial 
atherosclerosis, depression, venous thrombo-
embolism and diabetes [48, 49]. Many of these 
diseases negatively affect survival [48, 49] and 
quality of life [50].
IPF patients have a poor prognosis. Median 
survival before the introduction of antifibrotic 
agents was assessed at approximately 3.5 years, 
while the percentage of patients surviving 5 years 
after diagnosis was slightly above 30% [51]. This 
means that the prognosis can be poorer than in 
the case of many neoplastic diseases [52].
The prognosis in IPF patients can funda-
mentally improve as a  result of a wider use of 
antifibrotic agents [53–55].
One of commonly used methods for the as-
sessment of risk of death is the GAP score (gender, 
age, physiology — Table 4) [56].
After summing all points, an appropriate 
category should be assigned according to the 
Table 4B attached.
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Suspicion of interstitial 
lung disease
HRCT
CONFIRMATION OF INTERSTITIAL 
LUNG FIBROSIS
UIP Propable UIP Indeterminate 
for UIP
Non-UIP
Known potential 
cause of changes Established 
diagnosis
CLINICAL 
CONTEXT
BAL?
Biopsy
nd 
2 MULTIDISCIPLINARY 
DISCUSSION
Alternative 
diagnosis
IPF Exlusion of IPF
MULTIDISCIPLINARY DISCUSSION
Figure 6.	The	proposed	diagnostic	algorithm	for	IPF	(authors:	AJB,	WJP)
HRCT	—	high-resolution	computed	tomography;	UIP	—	usual	interstitial	pneumonia;	BAL	—	bronchoalveolar	lavage;	IPF	—	idiopathic	pulmonary	fibrosis
Basic rules for diagnosis
In order to diagnose IPF, one should:
— exclude known causes of ILD;
— confirm the presence of the UIP pattern in 
HRCT or, if the radiographic image is ambigu-
ous, of the UIP pattern in pathomorphological 
examination of lung biopsy [29].
Another important factor is the so-called 
clinical context, i.e. taking into account the fact 
that IPF is more frequent in men, tobacco smokers 
and people after the age of 60.
The proposed diagnostic algorithm for IPF is 
presented in Figure 6. 
Medical history taking and physical 
examination 
The absolute condition for establishing a dia-
gnosis is exclusion of known causes of interstitial 
fibrosis. Thorough history taking plays the most 
important role in this process. It must take into 
account possible exposure to bioaerosols and 
toxic substances at workplace, at home, in the 
immediate neighborhood or in places frequently 
visited by the patient [29]. The history taking 
should take into account whether the patient’s 
current or past occupation (this pertains also to 
distant pass) has been associated with a marked 
risk of developing lung changes, especially if it 
has involved exposure to asbestos, silica-con-
taining dusts, metal dusts and other harmful 
substances. Medical history should include co-
morbidities and symptoms associated with other 
organs (e.g. musculoskeletal or other suggestive 
of autoimmune causes). The question of using 
pneumotoxic drugs — currently and in the futu-
re — is of special importance. The risk of causal 
relationship can be assessed based on information 
gathered in medical databases such as Medline 
or Pneumotox.com.
It is extremely important to collect a detailed 
family history, aimed at determining the presence 
of ILDs in members of the immediate and more 
distant family.
Radiological examinations
A routine chest radiograph is usually the first 
stage of imaging diagnostics. It can be used to 
exclude other causes of abnormalities observed 
(e.g. heart failure, lung tumour). In some patients 
it is possible to identify changes suggestive of 
interstitial pulmonary fibrosis without significant 
clinical manifestation, which warrants further 
diagnosis.
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An imaging examination of key importance for 
IPF diagnosis is HRCT. An experienced radiologist 
can use its results to diagnose UIP pattern as well 
as indicate possible changes requiring differential 
diagnosis [29]. The recommended technique is 
a multi-detector CT based on volumetric acquisition, 
which allows multiplanar reconstructions and more 
thorough radiographic assessment of the nature of 
lung changes. The standard method is to perform 
the examination at deep sustained inspiration in 
the supine position, although in an early fibrosis 
stage, in order to differentiate from the so-called 
gravitational effect, an additional examination in 
the prone position is recommended. Additional 
scans in the expiration phase can be helpful in 
differential diagnosis to identify areas of so-called 
air trapping. Table 5 summarises the technical re-
quirements for HRCT used in the diagnosis of ILDs.
Lung biopsy
Currently, a common tendency is observed to 
limit the indications for SLB due to a significant 
risk of complications in this patient population. 
There is an ongoing discussion on cases when 
lung biopsy is indispensable, which is reflected in 
the disagreement between the Fleischner Society 
experts [31] and the current version of the inter-
national guidelines for IPF diagnosis [29]. The 
objective of SLB should be arriving at a diagnosis 
of a disease that can be treated in a specific way 
based on a pathomorphological diagnosis. A pro-
cedure suggestion must be based on an analysis 
of potential benefits and risks, and should take 
into account the patient’s general condition and 
comorbidities. Cryobiopsy may be considered 
a safer alternative for SLB.
The multidisciplinary nature of diagnosis
The international guidelines for IPF diagno-
sis stress the role of a multidisciplinary discus-
sion (MDD) in making decisions regarding neces-
sary diagnostic procedures (e.g. lung biopsy) as 
well as establishing the final diagnosis [29]. The 
basic composition of the multidisciplinary team 
should include a clinician (pulmonologist) and 
radiologist as well as pathologist in cases where 
lung biopsy has been performed. Specialists 
involved in the work of such a team should have 
extensive experience in diagnosing ILD, although 
a method to measure this experience has not been 
specifically defined. Many publications recom-
mend extending the team, if possible, to include 
a rheumatologist, thoracic surgeon (who should 
take part in assessing indications for SLB and 
choosing an optimum biopsy site), occupational 
medicine specialist (potential environmental 
exposure), cardiologist and other specialists 
depending on comorbidities, psychologist, ILD 
nurse as well as palliative care specialist. In spite 
of unequivocal international guidelines, a survey 
Table 5. The recommended computed tomography protocol in the diagnosis of ILD (Adapted from [29])
1.	Non-contrast	examinantion
2.	Volumetric	acquisition:
 —	 collimation	< 1 mm
 —	 the	shortest	possible	rotation	time
 —	 the	highest	possible	pitch	factor
 —	 voltage	and	current	appropriate	for	the	patient’s	size:
  •	typically	120 kVp	and	≤	240	mAs	
  •		lower	tube	potentials	(e.g.	100 kVp),	with	adjustment	of	tube	current	for	slim	patients
 —	 utilisation	of	available	techniques	limiting	unnecessary	radiation	(e.g.	tube	current	modulation)
3.	Reconstructions	of	thin-slice	images	(≤	1.5	mm):
 —	 continuous	or	overlapping
 —	 using	a high	spatial	frequency	algorithm
 —	 using	an	iterative	reconstruction	algorithm,	if	validated	on	the	CT	unit	(if	not	—	filtered	back	projection	should	be	used)
4.	Number	of	acquisitions:
 —	 in	the	supine	position:	inspiratory	(volumetric	acquisition)	—	obligatory
 —	 in	the	supine	position:	expiratory	(volumetric	or	sequential	acquisition)	—	optional
 —	 in	the	prone	position:	only	inspiratory	scans	(volumetric	or	sequential)	—	optional,	can	include	only	the	lower	lobes
5.	The	recommended	radiation	dose	for	volumetric	acquisitions	on	inspiration:
 —	 1–3 mSv	(e.g.	“reduced”	dose)
 —	 strong	recommendation	to	avoid	< 1 mSv	(ultra-low	doses)
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conducted among Polish pulmonologists before 
antifibrotic agents were commonly available 
demonstrated that only 55% of respondents 
establish IPF diagnosis in cooperation with a ra-
diologist and only 40% of diagnoses in patients 
following lung biopsy were discussed directly 
with a pathologist [58].
The final diagnosis should be clearly for-
mulated. One should also verify whether the 
diagnosis meets the required formal criteria or 
rather is a “working” diagnosis (one that does not 
fulfil the required formal criteria). In the latter 
case, one should specify whether the diagnosis is 
“definite” or “provisional/preliminary with high 
or low likelihood” [31, 59]. Sometimes even if the 
radiographic and pathomorphological criteria of 
UIP are met, the diagnosis has a working nature. 
This can stem, for instance, from inability to 
exclude in a reliable way the impact of environ-
mental factors or the risk of developing a systemic 
disease (in a dozen or so per cent of patients with 
connective tissue diseases (CTDs), lung changes 
precede the complete presentation of symptoms 
which allows the diagnosis of CTDs). Every 
patient with a working diagnosis of IPF should 
undergo periodic and systematic assessment for 
a possible change of diagnosis.
Table 6 presents the rules for diagnosing IPF 
if both HRCT and lung biopsy are available.
Diagnosis of IPF without lung biopsy
If during the diagnostic process (irrespec-
tive of the reason), no diagnostic pathomor-
phological material has been obtained, then 
the diagnosis should be made through a MDD 
taking into account all clinical factors (such as 
age, gender, history of tobacco smoking, course 
of the disease) and the available results of ad-
ditional tests and examinations (BAL, serologi-
cal tests and other deemed necessary based on 
a clinician’s suggestion). On this basis one can 
decide to make either a final or “working” IPF 
diagnosis [31].
Other diagnostic investigations
Other diagnostic investigations include tests 
of autoantibody titres performed in all patients 
with lung interstitial changes (antinuclear antibo-
dies — ANA, rheumatoid factor — RF) to identify 
those who require further assessments for connec-
tive tissue disease. Bronchoalveolar lavage (BAL) 
with cellular composition assessment can be used 
in differential diagnosis of ILDs. In certain cases, 
determination of serum concentrations of preci-
pitating antibodies makes it possible to confirm 
environmental exposure, which can be important 
in establishing the cause of ILD.
In all patients, a  full physical examination 
should be performed as it can be helpful in de-
termining a potential known cause of interstitial 
changes as well as diagnosing comorbidities. If 
needed, other specialists should be consulted. 
Another element of assessment are laboratory 
tests, such as complete blood count, urea, creati-
nine and electrolyte concentrations, urinalysis or 
liver function tests.
Table 6.  Idiopathic pulmonary fibrosis diagnosis based upon HRCT and lung biopsy patterns (Adapted from [29, 60], with 
modifications)
 Biopsy No biopsy 
UIP Probable	UIP	 Indeterminate	 Inconsistent	with	
the	UIP	pattern	
HRCT	 UIP	 IPF	 IPF	 IPF	 A different		
diagnosis	
IPF	
Probable	UIP	 IPF	 IPF	 IPF	likely*	 A different		
diagnosis	
IPF	likely*
Indeterminate IPF	 IPF	likely*	 Indeterminate** A different		
diagnosis	
Indeterminate**	
Inconsistent	with	
the	UIP	pattern	
IPF	likely*	 A different		
diagnosis	
A different		
diagnosis	
A different		
diagnosis	
A different		
diagnosis	
*The	final	diagnosis	can	be	made	through	a multidisciplinary	discussion.	The	following	configurations	of	demographic	and	clinical	characteristics	increase	the	likelihood	
of	IPF	diagnosis:	a)	moderate	to	serious	traction	bronchiectasis/bronchiolectasis	(of	mild	intensity	in	more	than	4 lobes	including	the	lingula	or	intensive	in	2	or	more	
lobes)	in	males	> 50 years	of	age	or	females	> 60 years	of	age;	b)	reticular	changes	affecting	> 30%	of	the	lung	area	in	HRCT	in	a person	> 70 years	of	age;	c)	an	
increased	neutrophil	percentage	or	absence	of	lymphocytosis	in	BAL
**If	biopsy	has	provided	no	signs	excluding	UIP,	no	biopsy	has	been	performed	or	the	material’s	quality	is	insufficient	for	diagnosis	while	medical	history	and	other	
examinations	have	excluded	the	influence	of	external	pneumotoxic	factors	or	diseases	associated	with	interstitial	changes	in	the	lungs,	the	current	classification	of	
interstitial	diseases	states	that	a diagnosis	of	unclassifiable	interstitial	lung	fibrosis	should	be	made	[1]
IPF	—	idiopathic	pulmonary	fibrosis;	HRCT	—	high-resolution	computed	tomography;	UIP	—	usual	interstitial	pneumonia
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Table 7. Basic features facilitating differentiation of IPF from selected ILDs leading to fibrosis
cHP CTD-ILD Pneumoconioses Interstitial changes  
associated with the use  
of pneumotoxic drugs
Medical 
history
In	some	patients	it	is	possible	to	
identify	potential	exposure.
Most	patients	present	
with	extrapulmonary	
symptoms
A history	of	exposure	to	
dusts
Interstitial	fibrosis	can	result	
from	long-term	exposure	to	
a drug,	often	lasting	many	
years
HRCT The	UIP	pattern	may	be	observed	in	
a chronic,	fibrotic	form	of	HP.
Extensive	areas	of	ground	glass	
appearance,	mosaic	attenuation,	air	
trapping,	centrilobular	nodules.
Predominantly	upper-zone	distribu-
tion	(although	predominantly	lower
-zone	distribution	is	also	possible),	
predilection	for	affecting	areas	surro-
unding	bronchovascular	bundles.
Common	coexistence	of	changes	
typical	for	the	acute	form
The	UIP	pattern	is	ob-
served	most	commonly	
in	RA.	
The	most	typical	feature	
of	lung	changes	in	the	
course	of	CTD	is	the	
NSIP	pattern.	
More	extensive	ground	
glass	areas	can	suggest	
CTD-ILD.	
Coexistence	of	exudative	
pleuritis	can	be	suggesti-
ve	of	CTD-ILD
The	UIP	pattern	can	be	
present	in	asbestosis.	
Local	thickenings	of	the	
pleura	called	pleural	
plaques	may	suggest	as-
bestosis.	Pleural	effusion	
or	pleural	mesothelioma	
can	coexist	with	the	pic-
ture	of	asbestosis
The	typical	UIP	pattern	is	
a rare	manifestation	of	drug-
-induced	lung	changes.
More	frequently	observed	
patterns	include	HP,	NSIP	
or	OP
BAL Severe	lymphocytosis,	more	often	in	
patients	with	active	exposure.	Patients	
with	a fibrotic	form,	when	the	exposu-
re	occurred	in	a distant	past,	can	have	
a normal	differential	cell	counts
Possible	lymphocytosis Possible	lymphocytosis,	
presence	of	asbestos	
bodies
Possible	lymphocytosis	and	
eosinophilia
Laboratory 
tests
Precipitins	can	be	positive,	but	they	
document	exposure	rather	than	pro-
ve	the	disease	diagnosis
Increased	titres	of	ANA,	
RF,	aCCP	and	other
autoantibodies	are	
suggestive	of	a CTD-ILD	
diagnosis.
The	diagnosis	should	be	
confirmed	by	a rheuma-
tologist
No	specific	studies
confirming
diagnosis
No	specific	studies
confirming
diagnosis
Clinical  
picture
Although,	in	most	cases	chronic	
fibrosing	HP	develops	in	more	advan-
ced	age,	disease	onset	at	a young	
age,	sometimes	in	childhood,	is	also	
possible
An	interstitial	disease	
can	precede	the	full	
picture	of	a CTD.	Usually	
symptoms	characteristic	
of	a specific	disease	
entity	are	present
Usually	progressive	
dyspnoea	and	cough	in	
an	individual	with	long-
term	occupational	expo-
sure.	Clinical	symptoms	
and	radiographic	chan-
ges	are	present	during	or	
after	the	exposure
Exposure	to	a harmful	drug	
is	associated	with	the	treat-
ment	of	comorbidities
Lung biopsy Peribronchial	distribution	of	changes,	
loosely	formed	granulomas,	lympho-
cytic	infiltrations,	empty	spaces	left	
by	washing	away	cholesterol	crystals
Presence	of	abundant	
lymphocytic	infiltrations	
with	visible	germinal	
centres
Asbestos	bodies HP,	OP,	NSIP
ILD	—	interstitial	lund	diseases;	cHP	—	chronic	hypersensitivity	pneumonitis;	CTD-ILD	—	connective	tissue	disease-associated	interstitial	lung	disease;	HRCT	—	
high-resolution	computed	tomography,	UIP	—	usual	interstitial	pneumonia,	RA	—	rheumatoid	arthritis;	NSIP	—	non-specific	interstitial	pneumonia;	OP	—	organizing	
pneumonia;	ANA	—	antinuclear	antibodies;	RF	—	rheumatoid	factor;	aCCP	—	anti-cyclic	citrullinated	peptide	autoantibodies
Differential diagnosis
Differentiation should include above all tho-
se disease entities which can be associated with 
a radiographic or histopathological pattern of UIP. 
First and foremost, differentiation should pertain 
to chronic hypersensitivity pneumonitis (cHP) 
[61], ILD in the course of CTD (CTD-ILD) (espe-
cially in the course of rheumatoid arthritis, RA) 
[62], pneumoconioses (especially asbestosis) [63] 
or drug-induced changes [22]. Table 7 presents 
the basic features of other diseases facilitating 
such differentiation.
The features useful in the differential dia-
gnosis listed in Table 7 should be understood as 
typical for individual disease entities, but their 
absence does not preclude a given diagnosis. In 
addition to the above disease entities, one should 
take into account very rare causes of the radio-
graphic UIP pattern, such as sarcoidosis [64] and 
other rare ILDs [65].
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Table 8. Selected forms of pharmacotherapy not recommended in IPF treatment based on the results of randomised trials 
Name of the drug Recommendation in the international 
guidelines 
Acronym References 
Interferon	gamma-1b	 Strongly	against	[10]	 INSPIRE	 [71]	
Colchicine	 Strongly	against	[10]	 	 [72]	
Cyclosporine	 Strongly	against	[10]	 	 [73]	
TNF-alpha	antagonist	(etanercept)	 Strongly	against	[10]	 	 [74]	
Oral	anticoagulants	(warfarin)	 Strongly	against	[75]	 ACE-IPF	 [68]	
Triple	therapy	(prednisone	+	azathioprine	+	NAC)	 Strongly	against	[75]	 PANTHER-IPF	 [67]	
Selective	endothelin-1	receptor	antagonist	(ambrisentan)	 Strongly	against	[75]	 ARTEMIS-IPF	 [70]	
Dual	endothelin	receptor	antagonist	(bosentan,	macitentan)	 Conditionally	against	[75]	 BUILD-3
MUSIC	
[76,	77]	
Phosphodiesterase-5	inhibitor	(sildenafil)	 Conditionally	against	[75]	 STEP-IPF	 [78]	
Single-target	tyrosine	kinase	inhibitor	(imatinib)	 Strongly	against	[75]	 IMATINIB-IPF	 [79]	
LOXL-2	inhibitor	(simtuzumab)	 Not	considered	 RAINIER	 [80]	
Differentiation of the UIP pattern from a fi-
brotic form of non-specific interstitial pneumonia 
(NSIP) can be another issue. Problems can arise 
from overlapping of radiographic features. For 
instance, IPF patients can present with limited 
ground glass areas (one of the radiographic 
features of NSIP). On the other hand, traction 
bronchiectasis is also often observed in NSIP 
patients. The presence of honeycombing areas in 
NSIP is also possible, although rare, and changes 
in both patterns are predominantly located in the 
lower lung zones. In addition, coexistence of both 
histopathological patterns may be observed in one 
lung biopsy [66].
Idiopathic pulmonary fibrosis treatment
Idiopathic pulmonary fibrosis treatment 
approaches have drastically changed in the last 
20 years. Furthermore, new reports are conti-
nuously emerging on the molecular pathomecha-
nisms and options of pharmacological interven-
tions. In the guidelines for the diagnosis and 
treatment of IPF of 2000, the only recommended 
pharmacotherapy methods were glucocortico-
steroids and immunosuppressants [9]. As new 
evidence arose indicating a  secondary role of 
inflammation and a primary role of fibrosis in 
the pathogenesis of IPF, a  search for new IPF 
treatment options began. Numerous randomised 
clinical trials have been conducted, proving lack 
of efficacy or even harmful effects of many treat-
ment regimens used. For instance, we currently 
have access to unequivocal data documenting 
harmful effects of glucocorticosteroids and im-
munosuppressants [67]. Despite this fact, the 
aforementioned survey demonstrated that in 2016 
23% of IPF patients in Poland received glucocor-
ticosteroids [58]. Negative results were obtained 
also in the ACE-IPF study, which demonstrated 
detrimental effects of warfarin use [68] in spite 
of encouraging results from earlier studies [69].
Negative results were also achieved in studies 
of an endothelin-1-receptor antagonist (ARTEMI-
S-IPF) [70]. Endothelin-1 is a cytokine involved 
in the pathogenesis of both IPF and pulmonary 
hypertension. Table 8 summarizes drugs which 
according to the current state of knowledge sho-
uld not be used in the treatment of IPF patients.
The breakthrough in IPF treatment was pos-
sible thanks to studies demonstrating the efficacy 
of pirfenidone [81, 82] and nintedanib [83]. These 
drugs, currently called antifibrotic agents, slow 
down the rate of fibrosis progression.
AE-IPF significantly worsen the prognosis. 
Most centres use high-dose glucocorticosteroids, 
often in combination with an immunosuppres-
sant. This treatment is recognised as the standard 
of care, although evidence supporting its efficacy 
is very limited [38]. For this reason, this docu-
ment omits the problem of the pharmacological 
treatment of IPF exacerbations.
Non-pharmacological treatment is an impor-
tant element of therapy. This mostly pertains to 
the treatment of chronic respiratory failure. In 
this document we discuss problems associated 
with the use of oxygen in individuals with re-
spiratory failure and with the use of ventilation 
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support in AE-IPF and in patients with end-stage 
respiratory failure. Pulmonary rehabilitation is 
another important and underestimated element 
of non-pharmacological treatment. Given the 
progressive nature of the disease, sooner or later 
every IPF patient requires palliative care.
MATERIAL AND METHODS
The Polish recommendations for diagnostic 
and therapeutic management were developed 
by a team of Polish experts in ILDs. The initia-
tive of developing national guidelines arose in 
a group of specialists in ILDs. It was sparked 
by nonunanimous opinions on IPF diagnosis, 
qualification for treatment, management using 
antifibrotics, supportive and palliative treat-
ment as well as methods for monitoring of the 
disease course. The initiative gained support by 
the General Board of the Polish Respiratory So-
ciety (PTChP, Polskie Towarzystwo Chorób Płuc) 
and the Head of the Interstitial Lung Diseases 
Section of the society.
The guidelines were created following two 
important publications: the Fleischner Society 
expert opinion published in February 2018 
[31], which contained suggested changes to the 
international guidelines for IPF diagnosis of 
2011 [10], and the final version of the updated 
international guidelines published in September 
2018 [29]. This publication was based on a sys-
tematic review of global literature, taking into 
account local factors resulting from the uniqu-
eness of the Polish healthcare system and the 
rules of the IPF treatment programme currently 
in place. The literature review was completed 
on 30th June 2019.
Objectives of the guidelines:
— improving the quality and reliability of IPF 
diagnoses;
— increasing antifibrotic treatment accessibility 
by popularising the diagnostic and treatment 
qualification criteria in Poland;
— creating conditions for optimal utilisation of 
Poland’s existing IPF treatment programme;
— identification of shortcomings and health 
needs in terms of IPF patient care.
The patient population to which the guideli-
nes pertain are patients with suspected or diagno-
sed IPF. The audience for whom the guidelines 
have been developed are doctors dealing with the 
subject matter of ILDs, especially pulmonologists, 
radiologists, pathologists, thoracic surgeons, 
pulmonary rehabilitation specialists, healthcare 
organisation specialists, representatives of the 
Polish National Health Fund (Narodowy Fun-
dusz Zdrowia) or other institutions shaping the 
healthcare politics in Poland.
Working team members: The working team 
comprises doctors specialising in ILDs, represen-
tative of various expert centres: pulmonologists 
(AJB, PWB, EJ, DJ, JK, KL, SM, MMM-B, WJP, EP, 
AS, MS, EW, DZ), radiologists (IB, PG, KO), patho-
logists (RL, MSz), as well as patients (DK, GW). 
The literature review regarding specific issues 
was prepared independently by authors assigned 
to a given task and by the author assigned to act 
as a librarian (AJB). WJP and AJB supervised the 
methodological consistency of the guidelines.
The methodology was adapted from the docu-
ment “Ramy metodyczne opracowywania zaleceń 
diagnostyczno-terapeutycznych” (Methodolo-
gical framework for developing diagnostic and 
therapeutic recommendations) published by the 
Agency for Health Technology Assessment and 
Pricing (Agencja Oceny Technologii Medycznych 
i Taryfikacji) [84]. The guidelines were developed 
according to the GRADE methodology (Grading 
of Recommendations Assessment, Development, 
and Evaluation) in a form similar to one used in 
the American Thoracic Society’s position [85]. 
Contentious issues were resolved using the Delphi 
method. At every development stage, the criteria 
described in the document “Narzędzie oceny wy-
tycznych AGREE II” (A tool to assess the AGREE 
II guidelines) were also taken into account [86].
The recommendations were divided into 
three parts: 1. Diagnosis; 2. Pharmacological tre-
atment; 3. Non-pharmacological and palliative 
treatment. The experts presented clinical problem 
suggestions in the form of a list of questions. The 
suggested questions were sent to all Editorial 
Board members, and the formulated clinical qu-
estions, after initial revisions and proofreading, 
were assessed in terms of their relevance. The 
score proposed by the authors of the Swiss Lung 
Disease Society consensus was used [87]. The 
importance of individual questions was evaluated 
in a 9-point score and grouped into the following 
categories: very important questions (8–9 points), 
important questions (6–7 points), unimportant 
questions (below 6 points). Questions considered 
by a majority as very important and important 
were subjected to further process.
Subsequently, a  working team was esta-
blished with an aim to develop individual 
guidelines: MMM-B, WJP — diagnosis; KL, SM, 
MS — pharmacological treatment; EP, AJB, AS, 
WJP — non-pharmacological treatment and 
palliative care.
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The review of available literature was per-
formed in the Medline and Cochrane databases. 
Existing systematic reviews were used as well as 
de novo reviews were made if a given systematic 
review was not available. The quality of evidence 
was determined as high, moderate, poor or very 
poor. The strength of recommendation was asses-
sed as strong or conditional [29].
The authors of respective sections develo-
ped the initial version of a response to a given 
question, accompanied by a short commentary. 
Subsequent versions were developed follo-
wing discussions via electronic means and 
face-to-face meetings. A preliminary version 
was sent out to all guideline authors for in-
ternal review.
The final version was sent for external review. 
After introducing final revisions, the work was 
sent to print. The English-language version was 
assumed as the original one. 
The recommendations will undergo planned 
revision every five years or earlier if new evidence 
emerges affecting in a significant way the state of 
knowledge on the diagnosis and/or treatment of 
IPF and an expert panel decides that it changes 
significantly the meaning of the previously pu-
blished recommendations, thus necessitating an 
earlier than planned update.
RECOMMENDATIONS
DIAGNOSIS
Question 1. Can IPF be diagnosed without 
lung biopsy in a patient with “probable UIP” 
HRCT pattern (without honeycombing, but 
with peripheral traction bronchiectasis or 
bronchiolectasis)?
Introduction
Analyses of patient populations meeting the 
“probable UIP” criteria in high-resolution com-
puted tomography (HRCT) indicate that lack of 
honeycombing should not exclude IPF diagnosis 
if all remaining radiographic features of the UIP 
pattern are present (especially predominantly 
subpleural and basal distribution of changes 
as well as the presence of bronchiectasis) [30, 
88–98]. The extent of reticular changes is of great 
importance. This is because if they exceed 1/3 
of the total lung volume (in a person above 60), 
the probability of IPF diagnosis exceeds 80%, 
with a 96% specificity [99]. The “probable UIP” 
pattern in HRCT co-exists with changes typical of 
definite or probable UIP in pathomorphological 
examination of SLB material in 82–94% of pa-
tients [88–90]. A recently published meta-analysis 
demonstrated that IPF diagnosis can be made in as 
many as 94% (87–99%) of patients with a radio-
graphic pattern corresponding to “probable UIP” 
[100]. The probability of IPF diagnosis increases 
in an appropriate clinical context, comprising the 
following: age above 60 years, a positive history 
of tobacco smoking (currently or in the past) and 
lack of other identifiable causes that could lead to 
interstitial fibrosis (especially lack of significant 
environmental exposure, chronic use of potential-
ly pneumotoxic drugs or signs of CTD) [31, 97, 99, 
101, 102]. In the group of patients with “probable 
UIP” (who had not undergone lung biopsy), an 
annual FVC decline was observed as well as a re-
sponse to antifibrotic treatment (with nintedanib) 
reducing the rate of this decline, comparable with 
outcomes observed in the “definite UIP” group 
(based on radiographic or pathomorphological 
presentation) [103]. 
Recommendation 1.
We suggest that a  “probable UIP” HRCT 
pattern, if it contains no changes suggestive 
of an alternative diagnosis, in an appropriate 
clinical context (e.g. male sex, smoking history, 
age above 60) and after excluding other causes 
of such changes, should be a sufficient basis for 
a multidisciplinary team to diagnose IPF with 
no need for diagnostic lung biopsy.
Quality of evidence: very poor
Strength of recommendation: conditional
Votes: strongly for (IPF diagnosis in the case 
of probable UIP with no need for diagnostic lung 
biopsy) — 6; conditionally for — 14; strongly aga-
inst — 1; conditionally against — 0; abstained — 0
Commentary
This recommendation is in line with the 
Fleischner Society’s position presented as a con-
sensus of an international group of experts in ILDs 
(including eight pulmonologists, six radiologists 
and three pathologists), which was developed 
based on a systematic literature review [31]. Ad-
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ditionally, this position is not inconsistent with 
the international ATS/ERS/JRS/ALAT recom-
mendations (2018), which suggests to consider 
invasive diagnosis (BAL or even SLB) in patients 
with the “probable UIP” HRCT pattern. Howe-
ver, the guidelines also allow the possibility of 
establishing IPF diagnosis without any invasive 
procedures, taking into account the clinical con-
text (presented in the above discussion) through 
a multidisciplinary discussion (MDD) [29, 104]. 
A  group of experts, including the co-authors 
of both documents, stress the fact that the re-
commendation to perform lung biopsy in case 
of “probable UIP” is conditional (with a poor 
strength of evidence) and in a  situation when 
the only missing element of the radiographic 
UIP pattern is lack of honeycombing while the 
other criteria are met and the clinical picture is 
highly suggestive of IPF, such a final diagnosis 
is highly likely. Surgical lung biopsy is an inva-
sive, costly procedure associated with possible 
complications, while it does not guarantee dia-
gnosis [105–109].
Question 2. Can a UIP pattern confirmed 
by pathomorphological examination of 
material collected through cryobiopsy 
be considered equivalent to a diagnosis 
made based on surgical biopsy?
Introduction
Surgical lung biopsy remains the gold stan-
dard in invasive diagnosis of ILD, including UIP/
IPF [29, 31]. In most situations, video-assisted 
thoracoscopic surgery (VATS) is preferred over 
open lung biopsy (OLB). Video-assisted thora-
coscopic surgery, like OLB, allows a controlled 
and precise choice of the biopsy site as well as 
achieving adequately sized (even several cen-
timetres) diagnostic material for examinations, 
which is especially important for appropriate 
pathomorphological assessment [110, 111]. The 
optimal management involves collecting mate-
rial in the form of numerous specimens, from 
different lobes, with a margin extending 1–2 cm 
away from the pleura [112–114]. Surgical lung 
biopsy is a procedure associated with risk that 
encompasses standard periprocedural complica-
tions (pneumothorax, bleedings), infections as 
well as, in the case of UIP/IPF patients, a higher 
risk of AE-IPF and also death [115, 116]. SLB-as-
sociated mortality depends on the advancement 
of disease, the need for mechanical ventilation, 
comorbidities, immunosuppressive treatment 
and the centre’s experience [117–119]. In spe-
cialist centres of the United States and England, 
the mean intrahospital mortality due to this dia-
gnostic procedure only was 1.7%, with mortality 
within 30 days after biopsy of 2.4% and within 
90 days of 3.9% [120, 121]. Transbronchial lung 
cryobiopsy (TBLC) is a new diagnostic technique 
[92, 122–126]. Its diagnostic effectiveness and 
complication rates are varied and depend on the 
experience of the person performing the proce-
dure [123, 125, 127–139]. The mean mortality 
due to this diagnostic procedure only has been 
estimated at 0.2%, with less frequent sudden 
exacerbations than in the case of SLB (1.2% vs 
6.1%). However, there are frequent complica-
tions of pneumothorax (0% vs 26% with TBLC; 
in the case of SLB, the rates of pneumothorax 
or persistent air leak are lower) and bleeding 
(on average, 5.3% vs 0.8% with SLB) [111, 123, 
128, 133, 135–145]. 
Recommendation 2.
We suggest that material collected for pa-
thomorphological examination through cry-
obiopsy, sufficient to diagnose UIP, should be 
considered equivalent to material from surgical 
lung biopsy.
Quality of evidence: very poor
Strength of recommendation: conditional
Votes: strongly for (accepting a UIP-confir-
ming result based on material from cryobiopsy) 
— 8; conditionally for — 11; strongly against — 0; 
conditionally against — 1; abstained — 1
Commentary
The international ATS/ERS/JRS/ALAT re-
commendations (2018) on IPF diagnosis do not 
take into account a situation where the patient 
is unable or unwilling to undergo SLB [29]. Ob-
servational studies based on IPF patient registries 
indicate that material for lung pathomorphologi-
cal examination is ever-more often collected using 
the TBLC method [146]. At present, the procedure 
is not commonly available or practiced, although 
there are ongoing attempts at its standardisation 
[147–149]. Material collected with this method is 
usually smaller than in surgical biopsy, with no 
possibility of choosing the precise biopsy site — 
it usually comes from the more centrally located 
areas [122]. The percentage of TBLC-based dia-
gnoses is up to 80–85% vs more than 95% in the 
case of diagnoses based on SLB [122–124].
The classical transbronchial lung biopsy 
(TBLB), given its low clinical effectiveness, 
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is not a recommended method for confirming 
the UIP pattern in pathomorphological exa-
mination. However, sometimes (in over one 
third of IPF patients) it is possible to use TBLB 
material to demonstrate changes correspon-
ding to elements of the UIP pattern (such as 
fibroblastic foci) [91, 127, 128, 138, 140, 150, 
151]. Although TBLB can be useful in certain 
situations, e.g. differential diagnosis (if changes 
inconsistent with UIP are present, in order to 
confirm an alternative diagnosis) [117], pro-
spective studies that would reliably determine 
the place of this method in UIP/IPF diagnosis 
are still lacking [29, 130].
Question 3. What respiratory function 
examinations should be performed 
to assess the risk of lung biopsy 
complications?
Introduction
In light of the current clinical practice and 
international guidelines for IPF diagnosis, in 
cases where non-invasive methods do not make 
it possible to establish diagnosis with a  satis-
factory level of confidence, it is recommended 
to perform pathomorphological examination of 
lung biopsy material [29]. At present, the re-
commended diagnostic procedure is SLB [29]. 
The invasiveness of this method is associated 
with a risk of complications (including disease 
exacerbations and even death) [152]. The iden-
tified risk factors for complications include: 
the male sex, non-elective or open procedure, 
requirement of mechanical ventilation following 
the procedure, preliminary diagnosis of IPF or 
connective tissue disease-associated ILD (CTD
-ILD), immunosuppressive treatment or TL,CO 
< 50% of predicted [105, 121, 153]. Another 
method providing tissue material of acceptable 
sizes is TBLC. This method is associated with 
a lower risk of death but also characterised by 
lower diagnostic effectiveness [123]. The na-
ture of its complications is also different (with 
more frequent bleedings and pneumothorax). 
The recognised risk factors for cryobiopsy 
complications include, among others, forced 
vital capacity (FVC) < 50% of predicted and 
carbon monoxide lung transfer (TL,CO) < 35% 
of predicted, serious hypoxaemia (PaO2 < 50–
60 mm Hg when breathing atmospheric air at 
rest), suspected pulmonary hypertension with 
> 40 mm Hg in echocardiographic examination. 
These factors are sometimes considered relative 
contraindications for the procedure [147, 148]. 
Recommendation 3.
We recommend that qualification for elec-
tive lung biopsy include arterial blood gas 
analysis, spirometry and assessment of transfer 
factor for carbon monoxide. 
Quality of evidence: very poor
Strength of recommendation: strong
Votes: strongly for (performing examinations 
to assess the degree of respiratory dysfunction be-
fore elective biopsy) — 11; conditionally for — 6; 
strongly against — 0; conditionally against — 0; 
abstained — 4
Commentary
In the case of biopsy, loss of lung parenchyma 
is small, and this element is not important for risk 
analysis. The suggested threshold values of lung 
function parameters to be used in qualification for 
diagnostic lung biopsy in patients with suspected 
IPF are arbitrary and have been chosen based on 
retrospective analyses and observational studies. 
In such a-priori studies, patients with very low 
values of functional parameters (FVC, TL,CO) and 
with respiratory failure, were excluded — that is 
why it is impossible to perform an assessment of 
the procedure safety with consideration of a wide 
range of FVC and TL,CO values. On the other hand, 
there is a safety analysis performed in 699 patients 
with ILDs. The analysis revealed that complica-
tions were not more frequent in patients with FVC 
< 50% of predicted and TL,CO < 35% of predicted 
compared with individuals with higher values of 
these parameters [154]. Pneumothorax was more 
frequent in patients with a higher radiographic 
fibrosis index and pathomorphological UIP dia-
gnosis, irrespective of FVC < 50% of predicted 
or TL,CO < 35% of predicted [154]. In light of the 
above, no definite recommendation can be given 
regarding threshold values defining an absolute 
contraindication for the procedure.
A separate problem associated with biopsy 
is an increased risk of AE-IPF. It is believed that 
when mechanical ventilation is used during any 
surgical procedure, intraoperative exposure to 
high oxygen concentrations (hyperoxia) and high 
pressures (barotrauma) or respiratory volumes 
(volutrauma) can increase recruitment of circu-
lating proinflammatory cells and mediators, thus 
intensifying the fibrotic process [155]. The reco-
gnised factors predisposing for an exacerbation 
in the periprocedural period include reduced 
FVC and TL,CO values, although it is impossible to 
name any specific factors that would constitute 
contraindications for biopsy [156].
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Question 4. Is it necessary to perform 
serological tests for autoimmune diseases 
in every patient with suspected IPF 
without clinical signs of connective tissue 
disease?
Introduction
Increased titres of ANA and RF are present in 
many IPF patients with no signs of CTD [157–161]. 
Many studies point to lack of significant diffe-
rences in the clinical course and prognosis of 
IPF patients with high antibody titres compared 
with IPF patients without antibodies [158, 161, 
162], although the most recent meta-analysis of 
9 studies (a total of 4602 IPF patients) indicates 
a higher risk of developing autoimmune disorders 
by patients with high titres of ANA and myelo-
peroxidase-specific anti-neutrophil cytoplasmic 
antibodies (MPO-ANCA) [163, 164]. Interstitial 
lung disease can be the first symptom of CTD in 
more than ten per cent of patients [165]. The UIP 
pattern is the most common pulmonary presenta-
tion of rheumatoid arthritis (RA) [166], but it can 
also occur in patients with systemic scleroderma 
[167, 168] and, much less frequently, in the course 
of other CTDs [169]. Similarly to IPF, lung changes 
among RA patients are more frequent in males 
and older patients and exhibit a relationship with 
tobacco smoking [166, 170–174]. Differentiation 
can be especially difficult in such cases if no 
extrapulmonary RA symptoms are present. 
Recommendation 4.
We recommend that every patient with 
suspected IPF undergo serological tests for au-
toimmune diseases.
Quality of evidence: very poor
Strength of recommendation: strong
Votes: strongly for (performing serological 
tests for autoimmune diseases in all patients 
with suspected IPF) — 14; conditionally for — 6; 
strongly against — 0; conditionally against — 0; 
abstained — 1
Commentary
The current international guideline for IPF 
diagnosis recommends performing serological 
tests in all patients with suspected IPF. This is 
a motherhood statement, i.e. a recommendation 
adopted a priori and not subjected to voting [29]. 
However, the guidelines fail to specify the exact 
tests that should be performed. It has been agreed 
that the basic serological tests include tests for 
antinuclear antibodies (ANA), rheumatoid factor 
(RF) and antibodies against cyclic citrullinated 
peptide (aCCP). Experts recommend that the 
panel be extended to include tests for other spe-
cific antibodies (e.g. a dermatomyositis-specific 
profile) depending on the clinical situation and 
diagnostic capabilities of a given facility [10, 29]. 
Patients with positive titres of ANA, RF, aCCP 
or other autoantibodies should be consulted by 
a rheumatologist and if connective tissue disease 
is preliminarily excluded, they should undergo 
periodic assessment for the development of an 
autoimmune disease. In patients with increased 
autoantibody titres (ANA > 1:320, RF > 60 U/L) 
but without other signs of autoimmune diseases 
and meeting other diagnostic criteria, a working 
IPF diagnosis should be established through 
a MDD and scrupulously monitored.
Question 5. Is it necessary to determine 
serum concentrations of specific 
immunoglobulins (precipitins) in order 
to diagnose hypersensitivity pneumonitis 
(allergic alveolitis) in every patient with 
suspected IPF?
Introduction
Radiographic changes in lung HRCT in pa-
tients with chronic hypersensitivity pneumonitis 
(cHP) can correspond to the radiographic UIP 
pattern. It was demonstrated that in as many as 
40% of patients with an initial IPF diagnosis, the 
diagnosis was changed to cHP after more thoro-
ugh examinations [175]. This makes it the most 
important disease entity that needs to be excluded 
in differential diagnosis of patients with suspec-
ted IPF. The identification of the antigen cause 
and source is of crucial importance for prognosis 
[176]. In everyday practice, the element of key 
importance is a scrupulously collected, systema-
tic medical history of possible exposures in the 
occupational and domestic environments as well 
as in the immediate neighborhood and frequen-
tly visited places [177, 178]. Unfortunately, it is 
estimated that in 50% of cHP cases the causative 
antigen remains unidentified [178–180]. A sugge-
stion was made to name this form a cryptogenic 
hypersensitivity pneumonitis [178].
One of recently published studies revealed 
positive results of a precipitin test for farmer’s 
lung in 78% of patients with an acute form, but 
only in 48% of patients with a chronic form [181]. 
Specific antibodies were detected only in 52% of 
pigeon breeders with a chronic form of lung di-
sease [182]. In a group of 86 bird breeders with 
Wojciech J. Piotrowski et al., Diagnosis and treatment of idiopathic pulmonary fibrosis
63www.journals.viamedica.pl
lung disease, the presence of specific immuno-
globulins was identified in 92% of patients (only 
in 2 radiographic signs of UIP were observed), 
while in the control group comprising healthy 
pigeon breeders specific antibodies were detected 
in as many as 87% of subjects [183]. By contrast, 
in the case of many patients with signs of cHP 
with positive results for specific antibodies, these 
antigens are not detected in the patients’ dome-
stic environments [184]. The value of positive 
precipitins in differentiation of cHP from other 
ILDs associated with pulmonary fibrosis was con-
sidered low (sensitivity: 72%, specificity: 68%) vs 
diagnosis made based on a MDD [185]. 
Recommendation 5.
We recommend that a test for the presence 
of specific immunoglobulins in the serum (pre-
cipitins) NOT be performed in all patients with 
suspected IPF. 
Quality of evidence: very poor
Strength of recommendation: strong
Votes: strongly for (performing a test for the 
presence of precipitins in the serum in all patients 
with suspected IPF) — 0; conditionally for — 0; 
strongly against — 11; conditionally against — 9; 
abstained — 1
Commentary
There is no need for assessing precipitins 
in all patients with a  radiographic pattern cor-
responding to UIP. It is especially unjustifiable 
to perform a wide panel of all available tests (for 
instance, performing a  test for farmer’s lung in 
someone who has never had any contact with 
rural environment is aimless). In HP a potential 
role is played by antigens present in the dome-
stic environment: avian antigens contained in 
bedding [180], nontuberculous mycobacteria 
[180] and fungal antigens [186]. For this reason, 
in justified cases, the domestic environment exa-
mination as well as choice of antibodies to test 
should above all take into account these antigen 
groups. However, detailed history taking is the 
most important element. It is justified to test for 
selected antibodies in the following situations: 
historical data pointing to possible exposure to 
antigens; presence of radiographic signs in HRCT 
suspicious of HP, such as ground glass, mosaic 
attenuation, air trapping; changes distributed pre-
dominantly in the upper and middle fields; young 
age of the patient; high lymphocyte percentage in 
BAL fluid [175, 177, 178, 187].
Question 6. Should bronchoalveolar 
lavage (BAL) be performed in every 
patient with suspected IPF?
Introduction
The cellular composition of BAL fluid in 
IPF patients does not have any characteristic 
features that would distinguish this disease 
entity from other ILDs [188]. Most patients are 
identified with an increased total cell count 
[189], increased neutrophil percentage > 5% 
[188, 190], increased eosinophil percentage 
> 2% [188], while the lymphocyte percentage 
is normal or slightly increased [188, 190]. Many 
authors point to a high lymphocyte percentage 
in BAL fluid (BALF) as a feature differentiating 
IPF from cHP [190, 191]. In a group of patients 
with ILDs it was observed that no IPF patient 
had a BALF lymphocyte percentage higher than 
25% [190]. Another study demonstrated that 
a BALF lymphocyte percentage > 30% was the 
cause of changing the diagnosis from IPF to 
non-specific interstitial pneumonia (NSIP) or 
chronic cHP [191]. However, the BALF lym-
phocyte percentage in patients with chronic 
(fibrotic) HP can be normal, especially when 
exposure that caused the (now completed) di-
sease occurred in the past. Other authors state 
that the BALF lymphocyte percentage in IPF 
patients can be increased and does not diffe-
rentiate IPF patients from those with cHP. For 
instance, in one study 18% of patients with the 
final diagnosis of IPF (biopsy-confirmed) the 
BALF lymphocyte percentage was above 40% 
[188]. In studies by Vasakova et al., the BALF 
lymphocyte percentage did not differentiate 
IPF patients from those with cHP — in both 
disease entities the median was 22–23% [192]. 
The lack of differences in the lymphocyte per-
centage between patients with IPF and cHP is 
also referred to by the authors of the current 
international IPF guidelines who support it with 
meta-analysis results [29]. 
Recommendation 6.
We suggest that bronchoalveolar lavage 
(BAL) NOT be performed in every patient with 
suspected IPF.
The examination is not necessary in pa-
tients with a  radiographic UIP pattern if the 
clinical context raises no doubt, but it can be 
helpful in differential diagnosis of ambiguous 
clinical or radiographic picture. 
Advances in Respiratory Medicine 2020, vol. 88, no. 1, pages 42–95
64 www.journals.viamedica.pl
Quality of evidence: very poor
Strength of recommendation: conditional
Votes: strongly for (performing BAL in all 
patients with suspected IPF) — 0; conditionally 
for — 2; strongly against — 6; conditionally aga-
inst — 13; abstained — 0
Commentary
If known causes of ILDs have been excluded 
and the radiographic image indicates UIP, the 
analysis of BALF cellular composition usually 
contributes little to the diagnosis. Even though an 
increased lymphocyte percentage decreases the 
likelihood of IPF diagnosis, it does not preclude 
it [188, 192]. On the other hand, in cHP patients 
the likelihood of increased lymphocyte percenta-
ges in BALF decreases with fibrosis progression 
[190]. An increased lymphocyte percentage may, 
however, suggest an alternative diagnosis [in the 
context of IPF diagnosis this is usually cHP, NSIP 
(idiopathic or associated with CTD), much less 
frequently sarcoidosis, drug-induced changes or 
pneumoconioses]. If cHP is suspected, it is im-
portant to identify a potential antigen since its 
elimination from the environment can significan-
tly alter the prognosis [176]. That is why patients 
with an increased lymphocyte percentage should 
undergo thorough assessment for environmental 
exposure.
The threshold value for lymphocytosis in 
BALF, which when exceeded should suggest 
a different diagnosis than IPF, is 25% according 
to the ATS/ERS guidelines dedicated to assessing 
the cellular composition of the BALF [193]. The 
current guidelines for IPF diagnosis of 2018 do not 
specify any cut-off value [29]. Exceeding the BALF 
eosinophil percentage above 25% can suggest 
acute or chronic eosinophilic pneumonia [193].
Question 7. What is the role of 
a multidisciplinary team in diagnosing 
IPF and who should be part of such 
a team?
Introduction
The current ATS/ERS/JRS/ALAT guidelines 
(2018) on IPF diagnosis attribute a very important 
role to a multidisciplinary discussion (MDD), 
which is suggested in case of every patient dia-
gnosed for ILD of elusive aetiology, with a clinical 
suspicion of IPF [29]. The agreement between 
a single discipline decision (SDD) and one made 
through a MDD is assessed at 70% (47–87%) 
[194–198]. A MDD can prevent the initiation 
of inappropriate treatment, delay of the correct 
therapy or redundant but potentially dangerous 
diagnostic procedures [29, 199, 200]. 
A multidisciplinary team involved in IPF 
diagnosis should always include a clinician (pul-
monologist) and radiologist as well as pathologist 
(in case of lung biopsy has been performed) — 
all should be experienced in ILD diagnosis, and 
if needed, also a  rheumatologist (possibility of 
CTD), occupational medicine specialist (potential 
environmental exposure), specialist in respira-
tory physiology, cardiologist (both helpful, for 
instance, in assessing the risk associated with 
invasive diagnosis) or another specialist whose 
assessment can be helpful in making diagnostic or 
therapeutic decisions [29, 87, 201–203]. A MDD 
in IPF diagnosis is of greatest importance when 
there is no unequivocal radiographic diagnosis 
of UIP (in HRCT) [29, 31, 204]. 
Recommendation 7A. 
We recommended establishing the dia-
gnosis in all patients diagnosed with signs of 
fibrosis due to ILD through a multidisciplinary 
discussion. 
Quality of evidence: very poor
Strength of recommendation: strong
Votes: strongly for (arriving at ILD diagnosis 
through a multidisciplinary discussion) — 13; 
conditionally for — 7; strongly against — 0; con-
ditionally against — 0; abstained — 1 
Recommendation 7B.
We recommend that a multidisciplinary 
team include at least a clinician (pulmonologist) 
and radiologist as well as pathologist (if lung 
biopsy has been performed). All team members 
should be experienced in the diagnosis of ILD. 
Quality of evidence: very poor
Strength of recommendation: strong
Votes: strongly for (the recommended make-
up of a multidisciplinary team) — 11; conditio-
nally for — 8; strongly against — 0; conditionally 
against — 0; abstained — 2
Commentary
The involvement of a MDD is considered 
the gold standard in the diagnostic process for 
IPF, especially in differentiation from other ILDs 
associated with fibrosis [1, 29, 31, 87, 201]. 
An appropriate assessment of the HRCT image 
forms the basis of IPF diagnosis. However, the 
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consistency of change assessment in reference 
to the UIP pattern is moderate even among expe-
rienced radiologists (especially at an early stage 
of the disease). That is why patients diagnosed 
due to suspected IPF should be referred to refe-
rence centres capable of providing diagnosis by 
an experienced team of doctors and organising 
a MDD, which facilitates establishing an adequate 
management approach [200, 205–208]. Someti-
mes a discussion of this type, offering a broader 
perspective on the disease contexts, leads to chan-
ging a previously made diagnosis [195, 197]. In 
cases where the radiographic image does not meet 
all the UIP criteria but corresponds to the “pro-
bable UIP” pattern, with an appropriate clinical 
context and lack of other lung changes, a MDD can 
be helpful in arriving at a diagnosis with no need 
for invasive diagnostic methods [31, 104]. In other 
cases, IPF can be diagnosed based on a combina-
tion of specific HRCT patterns in relation to the 
pathomorphological picture and clinical context. 
In such situations, the involvement of a multidi-
sciplinary team is also recommended [29]. If biop-
sy cannot be performed or the patient does not 
consent to it (in spite of existing indications), the 
diagnosis should be made through a MDD taking 
into account any clinical factors and available 
results of additional tests and examinations (BAL, 
serological tests and other deemed necessary). On 
this basis, depending on the likelihood of correct 
diagnosis, a decision can be taken to establish a fi-
nal IPF diagnosis (if it is definite) or a temporary, 
“working” one (if not all formal requirements have 
been met) [59]. A MDD should occur both before 
making a decision to use invasive diagnosis and 
after receiving pathomorphological examination 
results for a  lung fragment (if biopsy has been 
performed) in order to agree the most likely dia-
gnosis and further management. The seemingly 
best way to conduct a MDD is direct confrontation 
of opinions, but a discussion through electronic 
means (telemedicine) is also acceptable [31, 59].
Question 8. How to define disease 
progression?
Introduction
Idiopathic pulmonary fibrosis is a disease 
characterised by progressive interstitial fibrosis 
[10]. Progression rate clearly affects the progno-
sis. The course of disease is difficult to predict 
and can range from slow worsening of lung 
function parameters in a span of many years to 
a dramatically fast progression, leading to death 
within several months of diagnosis [209–211]. In 
addition, the course can be complicated with an 
acute exacerbation, which is associated with an 
approximately 50% mortality rate [38]. There are 
many ways to monitor progression, from assess-
ment of symptom severity and quality of life thro-
ugh questionnaires [209], to evaluation of fibrosis 
progression in imaging examinations (assessment 
of variations in the nature and extent of changes 
visible in HRCT at different intervals) [179, 212, 
213], to objective measurements of exercise ca-
pacity (e.g. changes of distance in the six minute 
walking test, 6MWT) [209], changes in the trans-
fer factor of the lung for carbon monoxide (TL,CO) 
and changes in vital capacity (usually forced vital 
capacity, FVC) [214, 215] within 6–12 months 
intervals. An absolute decline in FVC within 6 
or 12 months expressed in % of predicted is the 
most commonly used measure of progression. The 
reasons include the ease of measurement, repeata-
bility of results and a documented relationship 
with prognosis [179, 214–219]. An absolute FVC 
decline during the study is the primary endpoint 
in all major clinical trials of antifibrotics [82, 83, 
217, 218, 220, 221]. A decline in FVC ≥ 10% is 
a component of a composite endpoint (FVC decline 
or death) defining lack of treatment response [82, 
222, 223], and a lower rate of patients with a FVC 
decline ≥ 10% in the actively treated group com-
pared with the placebo group proves the efficacy 
of a treatment [222–224]. 
Recommendation 8.
We suggest that forced vital capacity (FVC) 
decline rate be recognised as the basic measure 
of IPF progression. A loss ≥ 10% of predicted 
value within 12 months or less is considered 
clinically relevant. 
Quality of evidence: poor
Strength of recommendation: conditional
Votes: strongly for (recognising the FVC dec-
line rate as the basic measure of IPF progression) 
— 8; conditionally for — 9; strongly against — 0; 
conditionally against — 0; abstained — 4
Commentary
There is no single ideal indicator that would 
define clinically relevant IPF progression. An 
absolute decline in FVC ≥ 10% from the baseline 
is the most commonly used, arbitrary measure of 
clinically relevant progression (which should not 
be confused with a clinically perceptible change) 
and is associated with a significantly higher risk 
of acute exacerbations and death. A comparison 
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of two methods for calculating FVC decline (ab-
solute decline, for instance from 80% to 70% of 
predicted vs relative decline by 10%, for instance 
from 4.0 L to 3.6 L, which with a predicted normal 
of 5.0 translates into a decline from 80% to 72% 
of predicted) indicates greater sensitivity of the 
relative index [225]. This means that thus defined 
number of patients with progression in a studied 
patient population will be higher, but there is 
also a  risk of overestimating the percentage of 
patients with clinically relevant progression. 
Both methods are characterised by a comparable 
predictive value of progression-free survival, 
progression being defined as requirement of 
transplant or death [225]. Many authors point 
to the fact that a decline in the range from ≥ 5% 
to below 10% is also associated with a poorer 
distant prognosis [226, 227]. Another frequently 
used measure of progression is a decrease in TL,CO 
≥ 15% or shortening of distance in the 6MWT 
by ≥ 50 m [224, 228]. A possible alternative to 
individual functional indices is the composite 
physiologic index (CPI), which takes into account 
the FVC, FEV1 and TL,CO values [222, 224, 229]. 
However, given the common use of spirometers, 
the ease of measurement, good repeatability as 
well as a well-documented relationship with pro-
gnosis, an absolute decline in FVC ≥ 10% within 
12 months or less should be considered the basic 
measure of clinically relevant progression [230]. 
When assessing progression based on pulmonary 
function tests, it is important to use the same 
reference values. Currently, it is recommended 
to use the Global Lung Function Initiative (GLI) 
reference values [231, 232].
PHARMACOLOGICAL TREATMENT
Question 9. Should IPF patients be 
treated with pirfenidone? 
Introduction
Pirfenidone is the first agent of antifibrotic 
agents to have been approved for IPF treatment. 
It’s main mode of action is inhibition of fibroblast 
activity and type I collagen production by affec-
ting TGF-b. The antifibrotic effects of this agent 
were initially demonstrated in non-randomised 
studies in the 1990s [233] and later confirmed 
in randomised, double-blind, placebo-control-
led trials. The first studies performed in Japan 
demonstrated deceleration of FVC decline in 
treated patients compared with the placebo gro-
up. A decreased rate of AE-IPF was also observed 
in the treatment group, which however was not 
confirmed in further studies [234, 235]. The 
agent was approved based on the results of three 
international multi-centre, randomised studies, 
CAPACITY 1 and 2 and ASCEND, involving close 
to 1300 patients. The results of the CAPACITY 2 
and ASCEND studies as well as a pooled analysis 
of all three trials confirmed the efficacy of the drug 
in patients with mild-to-moderate IPF. Patients 
with a severe form of the disease (FVC < 50% of 
predicted) were excluded from these trials. De-
celeration of FVC decline rate of approximately 
50% was demonstrated vs the placebo group, 
while a pooled analysis of patients in all three 
clinical trials demonstrated a  reduction in the 
risk of death in the treatment group by almost 
50% [81, 82]. Furthermore, post-hoc analyses 
of these trials in pirfenidone-treated patients 
revealed a  reduced number of hospitalisations 
due to respiratory causes and a  lower number 
of post-discharge deaths [236]. Pirfenidone also 
reduced worsening of dyspnoea, especially in 
patients with stages GAP II and GAP III, as well 
as severity of cough, one of the most bothersome 
symptoms experienced by IPF patients [223]. The 
proven benefits and safety of pirfenidone-based 
antifibrotic treatment allowed its approval for the 
treatment of IPF patients in 2011 in Europe and 
in 2014 in the US. The drug has received a con-
ditional recommendation in the international IPF 
treatment guidelines, supporting its use in the 
treatment of IPF patients [75]. 
Recommendation 9. 
We recommend the use of pirfenidone in 
IPF patients. 
Quality of evidence: moderate
Strength of recommendation: strong
Votes: strongly for (the use of pirfenidone 
in IPF patients) — 13; conditionally for — 6; 
strongly against — 0; conditionally against — 0; 
abstained — 2
Commentary
The results of randomised, placebo-contro-
lled studies as well as a pooled analysis of data 
gathered in these studies indicate that pirfenidone 
effectively slows down fibrosis progression in 
IPF patients [81, 82]. Pirfenidone is a safe drug, 
but one that can cause adverse effects. The most 
frequent ones include gastrointestinal symptoms 
(nausea, vomiting, lack of appetite, bodyweight 
loss) in approximately 20–40% of patients and 
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skin changes, especially rash associated with 
exposure to sunlight (in approximately 10%). 
An important but much less common treatment 
complication is elevated liver enzyme activity 
(approx. 3.5% of treated patients). In most cases, 
these effects are observed within the first six 
months of treatment. Their severity can be re-
duced through appropriate patient education as 
well as using preventive means and symptomatic 
treatment. If necessary, it is possible to reduce 
the pirfenidone dose or transiently interrupt the 
treatment, with no negative effects on its effica-
cy [237]. PASSPORT, a study designed to assess 
long-term safety of pirfenidone, failed to reveal 
any new adverse effects of the drug in addition to 
those already observed in randomised trials [238]. 
Contraindications include individuals diagnosed 
with hypersensitivity to the active substance or 
to any of the excipients; patients with a history 
of angioedema following pirfenidone administra-
tion; cases where simultaneous use of fluvoxa-
mine is necessary; serious hepatic dysfunction 
or end-stage liver disease; and serious renal dys-
function with endogenous creatinine clearance 
< 30 mL/min or requiring dialysis therapy. The 
initiation of pirfenidone treatment should always 
be preceded by a discussion with the patient, 
explaining the benefits of the treatment but also 
the risk of adverse effects. A decision to start the 
treatment should be made jointly by the doctor 
and the patient.
Question 10. Should IPF patients be 
treated with nintedanib?
Introduction
Nintedanib is a non-selective tyrosine kina-
se receptor inhibitor. It acts by simultaneously 
inhibiting three growth factor receptor fami-
lies involved in fibrogenesis and angiogenesis. 
These factors include platelet derived growth 
factor (PDGF), fibroblast growth factor (FGF) and 
vascular endothelial growth factor (VEGF) [239]. 
A clinical trial programme assessing the efficacy 
and safety of nintedanib in IPF treatment includes 
a  phase 2 trial, TOMORROW [240], and two 
replicated phase 3 clinical trials — INPULSIS-1 
and 2 [83], which collectively enrolled nearly 
1,500 patients who were treated for 12 months. 
The INPULSIS studies confirmed the efficacy of 
the drug in reducing the rate of FVC decline in 
patients, irrespective of their baseline clinical 
characteristics or degree of lung dysfunction (FVC 
> vs < 70% of predicted). The FVC loss observed 
during follow-up in the nintedanib-treated group 
was lower by approximately 50% than in the 
placebo group [241]. A pooled analysis of data, 
complemented with a meta-analysis of the above 
three randomised trials of nintedanib in the treat-
ment of IPF patients, additionally demonstrated 
that nintedanib treatment was associated with 
a reduction in the risk of an acute exacerbation 
of the disease (AE-IPF) by 47% compared to pla-
cebo, a trend towards reduced all-cause mortality 
and mortality due to respiratory causes as well 
as a  significant reduction in mortality during 
treatment [221]. At the same time, an acceptable 
safety profile of the treatment was observed. 
Long-term observational studies confirm the ef-
ficacy and safety of nintedanib treatment in IPF 
patients [242]. The proven benefits and safety of 
nintedanib-based antifibrotic treatment allowed 
its approval for the treatment of IPF patients in 
2014 in the US and in 2015 in Europe. The drug 
has received a conditional recommendation in the 
international IPF treatment guidelines, suppor-
ting its use in the treatment of IPF patients [75].
 
Recommendation 10.
We recommend the use of nintedanib in 
IPF patients. 
Quality of evidence: moderate
Strength of recommendation: strong
Votes: strongly for (the use of nintedanib 
in IPF patients) — 13; conditionally for — 6; 
strongly against — 0; conditionally against — 0; 
abstained — 2
Commentary
A programme of randomised, placebo-con-
trolled clinical studies [83, 221, 240] as well as 
long-term observational studies [242] confirms the 
beneficial effects of nintedanib on slowing down 
IPF progression and an acceptable safety profile of 
the treatment. The beneficial effect of the drug is 
comparable across all analysed subgroups of stu-
died subjects [241]. Nintedanib reduces the risk 
of AE-IPF, at the same time demonstrating a trend 
towards reduction of the risk of death [221]. This 
data supports the use of nintedanib in antifibrotic 
treatment of IPF patients. The main adverse ef-
fects reported by patients during nintedanib treat-
ment include diarrhoea, nausea, abdominal pain 
and vomiting [83, 240, 242]. Diarrhoea observed 
during treatment responds well to symptomatic 
treatment (loperamide), a temporary interruption 
of treatment or dose reduction. Liver function 
should be assessed before starting nintedanib 
and monitored during the treatment. The drug 
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should not be used in patients with liver injury 
(Child-Pugh classes B and C) and severe kidney 
failure. Since the drug’s mode of action involves 
the VEGF receptor, caution is recommended when 
treating patients with a history of cardiovascular 
diseases or increased risk of bleedings. Patients 
with a history of myocardial infarction or unsta-
ble angina pectoris in the last six months, and 
those receiving intensive antiplatelet treatment 
(> 325 mg/day of acetylsalicylic acid or > 75 mg/ 
/day of clopidogrel) or full anticoagulation the-
rapy were not enrolled into randomised clinical 
studies of nintedanib. Nevertheless, no contrain-
dication for nintedanib treatment in this patient 
population has been formulated, and a decision 
to start this treatment should be based on an 
analysis of the benefit-risk balance [243]. The 
initiation of nintedanib treatment should always 
be preceded by a discussion with the patient, 
explaining the benefits of the treatment but also 
the risk of adverse effects. A decision to start the 
treatment should be made jointly by the doctor 
and the patient.
Question 11. Can IPF patients be treated 
simultaneously with pirfenidone and 
nintedanib?
Introduction
The necessity of exerting pharmacological 
action on different profibrotic signalling pathways 
as a result of the multifactorial and complex path-
ogenesis of IPF suggest that better outcomes could 
be achieved with combination therapy. In recent 
years, several studies have been published asses-
sing the safety, tolerability and pharmacokinetics 
of combination therapy with pirfenidone and 
nintedanib in IPF patients [244–247]. In a  ran-
domised, double-blind phase 2 study conducted 
in a small group of 50 IPF patients, Ogura et al. 
[30, 57] demonstrated that combination therapy 
with pirfenidone and nintedanib had acceptable 
safety and tolerability profiles, which was con-
firmed in other studies [245–247]. A  Japanese 
study, however, revealed reduced values of the 
peak serum plasma concentration and area under 
the curve (AUC) of nintedanib when it was used 
simultaneously with pirfenidone [244]. However, 
further studies of the pharmacokinetics and safety 
of combination therapy with pirfenidone and 
nintedanib failed to reveal any pharmacokinetic 
interactions between these agents [245–247]. No 
randomised studies assessing the efficacy of com-
bination therapy with pirfenidone and nintedanib 
compared with monotherapy with either of the 
agents have been performed to date. Vancheri et 
al. only observed a  trend towards a  lower FVC 
decline in a group receiving simultaneous treat-
ment with nintedanib and pirfenidone, compared 
with a group treated with nintedanib alone [245]. 
Recommendation 11. 
Currently, we DO NOT recommend simul-
taneous use of pirfenidone and nintedanib in 
IPF patients. 
Quality of evidence: very poor
Strength of recommendation: strong
Votes: strongly for (simultaneous use of pi-
rfenidone and nintedanib in IPF patients) — 0; 
conditionally for — 2; strongly against — 8; con-
ditionally against — 7; abstained — 4
Commentary
There is scarce data on simultaneous tre-
atment with pirfenidone and nintedanib in IPF 
patients. Different modes of action and targets of 
pirfenidone and nintedanib suggest the possibility 
of further deceleration of FVC decline with their 
simultaneous use in the treatment of IPF. By con-
trast, in the case of combination therapy, there is 
a threat of unexpected or previously not observed 
toxicity as well as an increased risk of adverse 
effects, which partially overlap in the case of 
pirfenidone and nintedanib, especially as regards 
gastrointestinal disorders and increased liver en-
zyme activity [81–83, 240]. The currently available 
studies of the safety and tolerability of combina-
tion treatment with these drugs covering a period 
of only 12 to 24 weeks have failed to reveal any 
new, unexpected adverse effects, and most patients 
completed the planned combination therapy [245, 
246]. Given small study populations, a short dura-
tion of combination therapy assessment and lack of 
randomised studies of the efficacy of simultaneous 
treatment with nintedanib and pirfenidone as well 
as the high costs of simultaneous treatment with 
the two drugs, combination therapy only should 
be used within randomised clinical trials.
Question 12. Should patients diagnosed 
with IPF based on the clinical context and 
the “probable UIP” pattern in lung HRCT 
be treated with antifibrotic agents? 
Introduction
Data on the efficacy and safety of antifibrotic 
treatment in IPF patients with the probable UIP 
pattern in lung HRCT are significantly limited. 
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This is because this term was introduced into cli-
nical practice in 2018 [29, 31], after randomised 
phase 3 clinical trials of antifibrotics had been 
conducted. The terminology of radiographic pat-
terns was based at that time on the international 
guidelines for IPF diagnosis of 2011 [10], which 
did not differentiate the probable UIP pattern. 
Nevertheless, patients with a pattern of reticular 
changes characterised by basal and peripheral 
distribution (formerly, “possible UIP”) associa-
ted with peripheral traction bronchiectasis or 
bronchiolectasis suggestive of a fibrotic process 
but without the typical honeycombing in lung 
HRCT, which corresponds, in line with the cur-
rent nomenclature, to the “probable UIP” pattern 
[29, 31], were enrolled into randomised phase 3 
studies using nintedanib in IPF patients (approx. 
30% of subjects) [83]. A subgroup analysis taking 
into account clinical characteristics and results of 
pulmonary function examinations demonstrated 
consistent effects of nintedanib in this patient 
group (without honeycombing in imaging) and 
the group of patients with “definite UIP” (pre-
sence of honeycombing) in lung HRCT [248]. 
There is currently no data assessing the effects 
of pirfenidone in IPF patients with the “probable 
UIP” pattern in lung HRCT. However, observatio-
nal retrospective studies of IPF patients treated 
with pirfenidone indicate lack of differences in 
the effect on decelerated FVC decline between 
IPF patients with the “typical UIP” and “possi-
ble UIP” lung HRCT patterns [249] according to 
the nomenclature of radiographic patterns used 
in the previous international guidelines for IPF 
diagnosis of 2011 [10]. 
Recommendation 12.
We suggest that patients with IPF diagnosis 
established by a multidisciplinary team based 
on the clinical context and the probable UIP 
pattern in lung HRCT be started on antifibrotic 
agents. 
Quality of evidence: very poor
Strength of recommendation: conditional
Votes: strongly for (starting treatment with 
antifibrotic agents in patients with the proba-
ble UIP pattern) — 2; conditionally for — 15; 
strongly against — 0; conditionally against — 1; 
abstained — 3
Commentary
Retrospective analyses of randomised and 
observational studies demonstrated that reticular 
changes distributed peripherally and subpleu-
rally associated with traction bronchiectasis or 
bronchiolectasis but without honeycombing in 
lung HRCT, identified as “possible UIP” [10] 
or “probable UIP” [29, 31], in patients with an 
appropriate clinical context are very likely to 
represent the histopathological pattern of UIP in 
biopsy material. When assessing the probability 
of the histopathological UIP pattern in these pa-
tients, it is helpful to take into account the clinical 
probability of IPF, which is higher in individuals 
above 60 years of age, current or former tobacco 
smokers and persons with no history indicative 
of other potential causes of lung fibrosis [29]. In 
the above context and in light of the evolving dia-
gnostic recommendations on IPF, it seems justified 
to start antifibrotic treatment in patients with 
a diagnosis based solely on clinical assessment 
and the “probable UIP” pattern in lung HRCT. Out 
of the two drugs, nintedanib has better quality 
evidence for the efficacy of antifibrotic treatment 
in this patient population [248].
Question 13. Should IPF patients with 
mildly decreased or normal pulmonary 
function parameters be treated with 
antifibrotic agents?
Introduction
This problem has important implications for 
the efficacy and tolerability of the treatment. In 
most countries it is recommended to start treat-
ment on diagnosis, irrespective of symptoms or 
the degree of lung dysfunction. This is associated 
with inevitable disease progression whose rate is 
unpredictable. However, the randomised clinical 
trials enrolled patients with specific demographic 
and functional profiles, which makes extending 
their results to the general population more 
challenging.
The CAPACITY and ASCEND studies 
involved patients whose FVC was at least 50% 
of predicted and not above 90%. In a post-hoc 
analysis of these studies, the subjects were assi-
gned into subgroups depending on the degree of 
disease advancement: FVC < 80% of predicted 
(GAP II and III) or ≥ 80% (GAP I). An analysis 
of the placebo group revealed that disease pro-
gression was seen in patients with both higher 
and lower functional parameters. In the group 
receiving active treatment, patients of both sub-
groups experienced comparable benefits of using 
pirfenidone in terms of FVC decline rate and 
distance in the walking test [223, 250]. Japanese 
studies demonstrated that the greatest benefit of 
pirfenidone treatment was seen among patients 
Advances in Respiratory Medicine 2020, vol. 88, no. 1, pages 42–95
70 www.journals.viamedica.pl
with better preserved lung function (FVC ≥ 70% 
of predicted). Patients with less advanced stage 
of IPF more frequently maintained stable lung 
function, with less common worsening during 
pirfenidone treatment than patients with lower 
baseline lung function parameters [251–253]. 
The INPULSIS studies did not use the exclusion 
criterion of the upper limit of FVC% of predic-
ted. In these studies, an efficacy assessment was 
planned in pre-defined subgroups, for instance 
in individuals with FVC ≥  70% and <  70%. 
Equal treatment outcomes were demonstrated in 
patients with both lower and higher FVC values. 
In addition, post-hoc analyses demonstrated that 
nintedanib was equally efficacious in patients 
with FVC > 90% and < 90% [241, 254]. The 
INPULSIS-ON study, in which patients continued 
taking nintedanib for up to 192 weeks, also failed 
to reveal any differences in the therapeutic effect 
depending on the degree of FVC decline. 
Recommendation 13.
We suggest that antifibrotic treatment be 
proposed to IPF patients with mildly decreased 
or normal pulmonary function parameters. 
Quality of evidence: very poor
Strength of recommendation: conditional
Votes: strongly for (antifibrotic treatment of 
IPF patients with mildly decreased or normal 
respiratory functional parameters) — 2; conditio-
nally for — 16; strongly against — 0; conditionally 
against — 0; abstained — 3
Commentary
In each case before treatment is started, the 
benefits of the therapy and risk of adverse effects 
should be discussed with the patient. Antifibrotic 
agents slow down IPF progression while decre-
asing the rate of FVC decline. Thus, it seems logi-
cal to start the treatment when the lung capacity 
is still well preserved. However, treatment can be 
problematic to patients who do not experience 
any disease symptoms. An especially concerning 
aspect is the risk of adverse effects which can 
lower the quality of life. It is important to inform 
the patient about the nature of the disease, with 
its unpredictable course and the possibility that 
the rate of vital capacity decline increases at 
any moment. The patient should also be advised 
that even persons with low disease activity lose 
more FVC a year than healthy individuals [255]. 
In some situations, especially in patients who 
have been diagnosed incidentally, without any 
clinical symptoms and with normal functional 
test results, a decision can be made jointly with 
the patient to use the “watch and wait approach”. 
In such a case, however, lung function should 
be monitored regularly (every 3–6 months) and 
treatment should be started immediately after 
worsening is observed [87, 203, 256, 257]. Means 
of coping with adverse effects of the treatment 
should be discussed with the patient in particular 
detail. Given the possibility that a patient with 
normal results of lung function test may receive 
an antifibrotic for many years, it is necessary 
to inform them how they can reduce possible 
adverse effects.
Question 14. Should IPF patients with 
severe lung function impairment  
(FVC < 50% of predicted, TL,CO < 30% of 
predicted) be treated with antifibrotic 
agents?
Introduction
Randomised phase 3 clinical trials of pirfeni-
done (CAPACITY 004 and 006 and ASCEND) [81, 
82] and nintedanib (INPULSIS 1 and 2) [83] did 
not enroll patients with advanced IPF and serious 
lung dysfunction (FVC < 50% of predicted, TL,CO 
< 30% of predicted). Data on the efficacy and 
safety of antifibrotic agents in IPF patients with 
severe lung function impairment (FVC < 50% of 
predicted, TL,CO < 30% of predicted) are indeed 
limited. Nevertheless, an increasing body of 
evidence from observational studies using antifi-
brotic agents in this patient population indicates 
they have similar efficacy and adverse reaction 
profiles as those observed in pre-marketing ran-
domised clinical trials [253, 258–263]. This data 
supports antifibrotic treatment in IPF patients 
outside the range of pulmonary function para-
meters that was used in the inclusion criteria of 
randomised studies assessing the use of pirfeni-
done and nintedanib in IPF. 
Recommendation 14.
We suggest that antifibrotic treatment follo-
wing IPF diagnosis be proposed to all patients 
without contraindications for this treatment, 
irrespective of the degree of lung function im-
pairment. 
Quality of evidence: very poor
Strength of recommendation: conditional
Votes: strongly for (antifibrotic treatment 
of IPF patients irrespective of the degree of 
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lung dysfunction) — 3; conditionally for — 13; 
strongly against — 0; conditionally against — 3; 
abstained — 2
Commentary
A sudden decline in lung function or AE-IPF 
can occur at any stage of the natural history of the 
disease. Data from randomised clinical trials and 
observational studies involving the population of 
IPF patients indicate that antifibrotic agents are 
efficient in slowing down progressive lung func-
tion decline, irrespective of the baseline degree 
of respiratory dysfunction [81–83, 241, 250, 253, 
258–263]. The decision-making process regarding 
the initiation of pharmacotherapy should take 
into account the patient’s treatment preferences. 
Patients should be informed about the anticipated 
disease course as well as the benefits and po-
tential risks associated with starting antifibrotic 
treatment. Discussing the treatment limitations 
and achievable goals is especially important. It is 
key for the patient to understand that pharmaco-
logical treatment will not improve lung function 
but only slow down disease progression and that 
the patient will likely fail to experience much 
improvement in terms of disease symptoms and 
quality of life. The choice of an antifibrotic agent 
for IPF treatment should take into account the 
patient’s individual preferences, comorbidities 
and concomitant treatment. Patients with serious 
comorbidities associated with a poor prognosis 
and short life expectancy will most likely not 
benefit from antifibrotic treatment.
Question 15. Is disease progression 
an indication for discontinuation of 
antifibrotic treatment?
Introduction
IPF is a  chronic progressive disease and 
the currently used antifibrotic treatment offer 
no curative potential but only deceleration of 
disease progression [81–83, 240]. Based on cli-
nical trials, it was assumed that an absolute FVC 
decline by ≥ 10% indicates insufficient treatment 
response. On this basis different local regulations 
and guidelines recommend discontinuation of 
pirfenidone or nintedanib in case of disease pro-
gression, i.e. an FVC decline by ≥ 10%, within 
12 months of treatment [82]. The published po-
oled data from the CAPACITY and ASCEND trials 
provided evidence that continuation of pirfeni-
done treatment is beneficial to IPF patients who 
have experienced significant disease progression 
during treatment (defined as an FVC decline by 
≥ 10% within 6 months of treatment), in the form 
of a reduced risk of further FVC decline or death 
[264]. Similar pooled data from the INPULSIS 
I and II studies, suggestive of treatment benefits 
despite reduced FVC, are available for nintedanib 
[265]. A recently published study assessed the 
frequency of multiple disease progression events 
within 12 months. The progression events were 
defined as a relative reduction in FVC by ≥ 10% 
of predicted, absolute reduction of distance in the 
6MWT by ≥ 50 m, hospitalisations due to respira-
tory cause or death of any cause. It was demon-
strated that pirfenidone significantly reduced the 
frequency of multiple progression events or death 
after any progression event within 12 months 
of treatment versus placebo [266]. The above 
study results suggest that continued antifibrotic 
treatment benefits IPF patients despite disease 
progression during the treatment. 
Recommendation 15.
We suggest that disease progression NOT be 
an indication for discontinuation of antifibrotic 
treatment. 
Quality of evidence: poor
Strength of recommendation: conditional
Votes: strongly for (recognising disease pro-
gression as an indication for discontinuing an-
tifibrotic treatment) — 0; conditionally for — 2; 
strongly against — 5; conditionally against — 11; 
abstained — 3
Commentary
Currently, there is no unambiguous, com-
monly accepted definition of disease progres-
sion and, consequently, of antifibrotic treatment 
failure. The assessment of antifibrotic treatment 
efficacy in clinical trials was based on a  long-
term analysis of FVC, although it is known that 
this parameter is characterised by a certain in-
trapersonal variability. In addition to pulmonary 
function parameters (FVC, TL,CO) a comprehensive 
assessment of the disease course should take into 
account other parameters, such as clinical symp-
toms (dyspnoea, cough, exercise capacity, etc.), 
possible complications (such as exacerbations, 
hospitalisations, pulmonary hypertension) or 
imaging examination results (HRCT). In a po-
oled analysis of the CAPACITY and ASCEND 
trials, Nathan et al. confirmed that FVC in long-
term follow-up of IPF patients is characterised 
by a  marked intrapersonal variability, which 
prevents a  reliable assessment of therapeutic 
response using a  series of FVC measurements 
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[264]. In addition, it should be stressed that even 
though a decline in FVC by ≥ 10% is indisputably 
significant, it does not prove lack of treatment 
efficacy. This is because it cannot be ruled out 
that a much larger FVC decline would have been 
observed if no treatment had been provided. The 
presented results of a pooled analyses of the above 
clinical trials proved that disease progression in 
IPF patients undergoing antifibrotic treatment 
should not be interpreted as treatment failure 
leading to discontinuation as long as tolerability 
is satisfactory [265]. No data is currently available 
on whether it is more beneficial to continue the 
same treatment or switch agents in case of disease 
progression. In case of further deterioration of 
respiratory function, it is recommended to refer 
the patient to a transplant centre unless contra-
indications for lung transplant exist [264, 266]. 
Question 16. In what situations should 
one consider switching from one 
antifibrotic agent to the other?
Introduction
It was demonstrated that both pirfenido-
ne and nintedanib slow down IPF progression 
expressed as a reduced FVC decline over time. 
However, no head-to-head trials comparing both 
agents have been conducted to date [82, 83]. The 
choice between the two drugs is, therefore, based 
on the experience of the treating pulmonologist, 
contraindications and adverse effect profile of 
a  given antifibrotic, concomitant use of other 
drugs and possible interactions as well as the 
patient’s preferences. A possible justification 
of switching one drug for the other is the deve-
lopment of unacceptable adverse effects or lack 
of efficacy. This, however, must be adjudicated 
with great caution. The problem of defining IPF 
progression during antifibrotic treatment is di-
scussed in Question 8. Treatment-related adverse 
events for pirfenidone and nintedanib partially 
overlap, especially as regards the gastrointestinal 
system (nausea, vomiting, diarrhoea) or increased 
liver enzyme activity as well as bodyweight loss. 
On the other hand, pirfenidone is additionally 
associated with skin adverse effects such as rash 
or photosensitivity reaction. Adverse effects as-
sociated with antifibrotic treatment are usually 
mild to moderate and adequate management 
(dose reduction, short treatment interruption or 
symptomatic management) makes it possible to 
continue the treatment in most patients. Clinical 
studies suggest that treatment-related adverse 
events were the cause of discontinuation in 15% 
of pirfenidone-treated [82] and 19% of ninteda-
nib-treated cases [83]. The availability of two 
antifibrotic agents makes it possible to switch 
between the treatments in certain cases. Data 
on the switching of antifibrotic agents is limited 
and it pertains to switching from pirfenidone to 
nintedanib due to adverse effects or disease pro-
gression [267–269]. The above studies indicate 
that in selected patients who do not tolerate pirfe-
nidone treatment, switching to nintedanib can be 
associated with good tolerability of the treatment 
in spite of the similar adverse effect profiles of 
both agents. It was additionally observed that 
individual responses to treatment with any of the 
drugs can differ. It was demonstrated that patients 
who were stable during the treatment with one 
of the antifibrotic agents experienced progression 
when using the other [268].
 
Recommendation 16.
We suggest switching from one antifibrotic 
agent to the other in case of significant lack of 
tolerance or adverse effects. 
Quality of evidence: very poor
Strength of recommendation: conditional
Votes: strongly for (changing an antifibrotic 
agent in case of intolerance or adverse effects) — 
4; conditionally for — 15; strongly against — 0; 
conditionally against — 0; abstained — 2
Commentary
The first drug to have been approved in the 
treatment of IPF in Europe was pirfenidone. This 
happened in 2011 [270], after the publication of 
the CAPACITY study results [82]. That is why 
most patients in many centres providing IPF tre-
atment were at first qualified for this treatment. 
The second agent to have been approved for IPF 
treatment in Europe was nintedanib, in 2015. This 
posed several important questions to pulmono-
logists, for instance, which of the agents should 
be used first and when switching from one agent 
to the other should be considered. Long-term 
open-label studies, pooled analyses of earlier 
randomised clinical studies and real-world data 
confirmed the beneficial safety and tolerability 
profiles of both pirfenidone [237, 238, 271, 272] 
and nintedanib [242, 267]. However, in a certain 
percentage of patients — in spite of dose adjust-
ments, interruptions or symptomatic manage-
ment — the treatment is discontinued because 
of persistent adverse effects. Despite the partial 
overlapping of the adverse effects of pirfenidone 
and nintedanib, different pharmacodynamic and 
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pharmacokinetic properties of the agents make it 
possible to switch the treatment safely in selected 
patients [242, 267]. No data on switching from 
nintedanib to pirfenidone has been published 
to date. Studies analysing nintedanib treatment 
in patients previously treated with pirfenidone 
additionally revealed there was an intrapersonal 
variability of responses to treatment, from stable 
to progressive disease, depending on the agent 
used [268]. In case of adverse effects preventing 
the use of one of the antifibrotic agents or dise-
ase progression, it seems worthwhile to consider 
switching from one antifibrotic to the other after 
assessing the anticipated risks and benefits and 
discussing it with the patient. In order to answer 
the question whether switching from one agent 
to the other in case of disease progression could 
be beneficial to IPF patients, prospective, rando-
mised clinical trials are necessary.
Question 17. Should all IPF patients be 
treated with anti-acid agents?
Introduction
It is known that an increased frequency of 
gastroesophageal reflux disease (GERD) is ob-
served in IPF patients. Studies have revealed 
that more than a half of patients with acid reflux 
experience symptoms of the disease. However, 
the severity of the gastroesophageal reflux (GER) 
is not correlated with severity of IPF. Moreover, 
in more than 60% of patients receiving standard 
anti-reflux treatment (AAT), episodes of low oeso-
phageal pH are still observed [41]. Discussions 
about the causal relationship between GERD and 
IPF are ongoing [17]. The use of agents inhibiting 
hydrochloric acid secretion (proton pump inhibi-
tor (PPIs), H2 blockers) in IPF patients has been 
an object of interest for years. PPIs are drugs of 
pleiotropic properties. In vitro studies demonstra-
ted that they inhibit pro-inflammatory cytokines, 
adhesive molecules and metalloproteinases and 
induce cytoprotective enzymes, at the same time 
inhibiting fibroblast proliferation and decreasing 
collagen production stimulated by TGF-b [273]. 
Thus, the effect of PPIs in IPF patients is not 
necessarily linked with suppression of acidic 
GER but with additional anti-inflammatory and 
antifibrotic effects of these agents. The results 
of several retrospective studies indicate a longer 
survival in IPF patients taking AAT [274, 275] as 
well as a lower rate of FVC decline and reduction 
in acute exacerbations [276]. A meta-analysis of 
13 observational studies assessing the effects of 
pharmacological treatment of reflux disease on 
the course of IPF demonstrated that using agents 
reducing gastric acid secretion caused a signifi-
cant reduction in IPF-associated mortality as well 
as prolonged survival without lung transplant. 
However, no influence on all-cause mortality or 
pulmonary function parameters was observed. On 
the other hand, in patients with FVC < 70% of 
predicted a significant increase in the incidence 
of respiratory infections was observed. No rando-
mised, placebo-controlled study was found that 
would assess the effects of anti-reflux treatment 
on the course of IPF. Therefore, the results of 
this meta-analysis should be interpreted with 
caution [277]. In addition, in some observational 
studies the presence of so-called immortal time 
bias was demonstrated — in order to undergo 
assessment, the subjects had to survive until the 
endpoint, which created a  false impression of 
the drug’s protective properties [278]. Despite 
numerous controversies and lack of randomised 
trials assessing their efficacy, the international 
guidelines of 2015 conditionally recommend 
regular use of AAT in IPF treatment, regardless 
of GERD symptoms [75]. 
Recommendation 17.
We suggest that anti-acid agents in IPF 
patients NOT be used in absence of other indi-
cations for such treatment. 
Quality of evidence: very poor
Strength of recommendation: conditional
Votes: strongly for (the use of anti-acid agents in 
IPF patients without indications for such treatment) 
— 0; conditionally for — 0; strongly against — 1; 
conditionally against — 17; abstained — 3
Commentary
Post-hoc analyses of randomised clinical 
studies of using pirfenidone and nintedanib in 
IPF treatment were free of immortal time bias and 
yielded opposite results on the protective role of 
AAT. Among IPF patients who received pirfenido-
ne as part of three clinical phase 3 trials, nearly 
44% took also agents inhibiting hydrochloric acid 
secretion. No differences were observed in any 
of endpoints assessing IPF progression between 
groups treated with PPIs and those not receiving 
this treatment. On the other hand, PPI-treated 
patients presented with more serious gastrointe-
stinal adverse effects [228]. Similarly, an analysis 
of the placebo-treated groups in these same rando-
mised trials failed to demonstrate any difference 
in the number of deaths, hospitalisations or FVC 
decline rate. An insignificantly higher rate of 
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infections, including respiratory infections, was 
observed in patients receiving PPIs [75]. Patients 
participating in the INPULSIS studies, irrespec-
tive of whether they were taking or not agents 
reducing hydrochloric acid secretion, were found 
to exhibit no changes in the natural history of 
the disease (placebo group) or the effect of these 
agents on nintedanib efficacy. Similarly to pirfe-
nidone studies, an insignificantly higher rate of 
respiratory infections was observed in patients 
receiving PPIs [279]. The treatment of cough 
associated with IPF is a  separate issue. Cough 
is known to be one of the most bothersome and 
most difficult-to-treat IPF symptoms. GERD can 
exacerbate cough. A single-centre, randomised, 
double-blind, placebo-controlled clinical trial 
was conducted to assess the efficacy of omepra-
zole in reducing cough episodes in IPF patients. 
A 39% decline in the rate of cough attacks was 
demonstrated in the omeprazole-treated group. 
No changes were observed in FVC, TL,CO or quality 
of life assessments during three months of follo-
w-up. The study results can support the efficacy 
of omeprazole in managing cough in IPF patients 
and indicate a need of additional, multicentre 
trials with larger patient populations [280].
Question 18. Should N-acetylcysteine be 
used in IPF treatment?
Introduction
N-acetylcysteine (NAC) is a drug of antioxi-
dant properties, a precursor of glutathione which 
is the basic endogenous antioxidant. In vitro and 
animal studies indicated that NAC inhibited the 
profibrotic effects of TGF-b on tissues and trans-
formation of epithelial cells into mesenchymal 
cells [281, 282]. For this reason, it was believed 
that NAC use in IPF patients in whom the TGF-b 
action is an important disease mechanism would 
result in suppression of fibrosis and improvement 
in lung function parameters. The recommenda-
tions for NAC use in IPF patients were based on 
the results of the IFIGENIA study, which demon-
strated that patients receiving NAC in combina-
tion with prednisone and azathioprine had a lo-
wer FVC decline during 12 months of treatment 
than placebo-treated patients. In addition, lower 
myelotoxicity of immunosuppressive treatment 
was seen in these patients, albeit with no differen-
ces in survival [283]. The results of the IFIGENIA 
study led to widespread use of triple instead of 
double therapy in IPF patients. In order to assess 
the efficacy of NAC monotherapy compared with 
triple therapy, the PANTHER-IPF study was desi-
gned. In this study, patients received NAC alone, 
placebo or NAC, prednisone and azathioprine. 
The PANTHER-IPF study demonstrated that triple 
treatment is associated with higher mortality and 
hospitalisation rate than NAC or placebo, and for 
this reason the study was discontinued [67]. Ho-
wever, the comparison of the placebo group with 
NAC monotherapy group was continued and no 
significant differences in the course of IPF were 
seen in the two patient groups [284]. Subgroup 
analysis assessing the influence of polymor-
phisms of single TOLLIP genes demonstrated that 
patients with the TT genotype of the rs3750920 
gene (TOLLIP) can benefit from NAC treatment, 
but NAC administration in patients with the CC 
genotype is associated with worsening of lung 
function. Therefore, the use of NAC in IPF pa-
tients should be preceded by a polymorphism 
analysis of the TOLLIP gene [285]. 
Recommendation 18.
We recommend that N-acetylcysteine NOT 
be used in the treatment of IPF patients, either 
as monotherapy or in combination with other 
agents. 
Quality of evidence: poor
Strength of recommendation: strong
Votes: strongly for (the use of N-acetylcyste-
ine in IPF patients) — 0; conditionally for — 0; 
strongly against — 11; conditionally against — 6; 
abstained — 4
Commentary
There are contradicting reports on combina-
tion therapy with NAC and pirfenidone. One Japa-
nese study that enrolled patients with advanced 
disease who had experienced FVC decline ≥ 10% 
within 6 months preceding the study demonstra-
ted that the add-on of inhaled NAC caused decele-
ration of FVC decline rate compared with a group 
taking pirfenidone alone. However, it was a case-
control study and the study population was very 
small [286]. In another study, among patients with 
an early IPF form, the efficacy of inhaled NAC was 
observed in individuals with FVC < 95% of pre-
dicted and TL,CO < 55% of predicted [287]. On the 
other hand, the PANORAMA study, a multicentre, 
double-blind, placebo-controlled study involving 
123  IPF patients, failed to reveal any positive 
effect of administering oral NAC at a dose of 3 × 
600 mg in combination with pirfenidone. NAC 
failed to improve pirfenidone tolerability, and in 
the group receiving both agents, FVC decline was 
even higher than in the pirfenidone monotherapy 
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group [288]. The most recent recommendations 
for the treatment of IPF [75] sustained the earlier 
position on NAC treatment as contraindicated 
in most IPF patients. The use of NAC would be 
justified in patients with the TT genotype of the 
TOLLIP gene, although targeted therapy is not 
currently used. 
Question 19. Should IPF patients receive 
immunosuppressive treatment?
Introduction
The initial concept of the disease process 
involved in IPF as having a largely inflammato-
ry nature led to the use of immunosuppressive 
treatment. In the past, immunosuppressive tre-
atment was considered an important element of 
IPF management and recommended in the first 
international diagnostic and therapeutic recom-
mendations [9]. Despite the widespread past use 
of glucocorticosteroids (GCS) in IPF treatment, 
there are no randomised, placebo-controlled 
trials of adequate quality that would support 
their use in this indication [289]. In a  similar 
vein, a systematic review of studies using other 
nonsteroidal immunosuppressive drugs, such as 
cyclophosphamide, azathioprine (AZA) or in-
terferon-g, failed to demonstrate their beneficial 
effects in the treatment of IPF patients [290]. 
Moreover, the once widely used triple treatment 
with prednisone, AZA and NAC proved to be as-
sociated with higher rates of hospitalisations and 
deaths compared with placebo [67]. Based on the 
current international IPF treatment guidelines, 
immunosuppressants received a strong recom-
mendation against their use in the treatment of 
IPF patients [75]. 
Recommendation 19. 
We recommend that NO type of immuno-
suppressive treatment be used in IPF patients. 
Quality of evidence: poor
Strength of recommendation: strong
Votes: strongly for (the use of immunosup-
pressive treatment in IPF patients) — 0; conditio-
nally for — 0; strongly against — 12; conditionally 
against — 6; abstained — 3
Commentary
Attempts at using immunosuppressant in 
the treatment of IPF patients have been made in 
the past usually in relation to the original theory 
which linked the pathobiology of IPF at least in 
part with inflammation. Few available studies, 
often of low quality, failed to demonstrate any be-
nefit of such an approach. However, many adver-
se effects associated with this treatment were 
demonstrated and even, as in the case of triple 
treatment (GCS + AZA + NAC), an increased 
risk of death in actively treated patients [67]. 
Given lack of evidence confirming any benefits 
and observed toxicity, the use of immunosup-
pressive treatment in IPF should be considered 
harmful and inconsistent with evidence-based 
medicine [289, 290].
Question 20. Should agents dedicated to 
treating pulmonary hypertension be used 
in IPF patients?
Introduction
Pulmonary hypertension, defined as mean 
pulmonary artery pressure ≥ 25 mm Hg, is frequ-
ent in IPF patients, especially in an advanced 
stage of the disease or in case of concomitant em-
physema [291, 292]. At diagnosis, approximately 
8–15% patients have concomitant pulmonary hy-
pertension [46, 293], and this percentage reaches 
30–50% during qualification for transplant [292, 
294, 295]. The presence of pulmonary hyperten-
sion in IPF patients is associated with increased 
mortality, more severe dyspnoea, decreased 
exercise tolerance, TL,CO impairment, more severe 
hypoxaemia and increased risk of an AE-IPF [294, 
296]. Several randomised clinical trials assessed 
treating IPF patients with different drugs used 
in pulmonary hypertension but yielded negative 
results. As regards the treatment of IPF-associated 
pulmonary hypertension, lack of efficacy was de-
monstrated in the case of dual endothelin receptor 
antagonists (bosentan and macitentan) [76, 77, 
297]. The selective antagonist ambrisentan, asses-
sed in the ARTEMIS-IPF study and the terminated 
ARTEMIS-PH study, demonstrated lack of efficacy 
in the treatment of pulmonary hypertension and 
increased the frequency of hospitalisations due 
to respiratory causes [70]. A phase 2 study of 
riociguat, a soluble guanylate cyclase stimulator, 
in ILDs with symptomatic pulmonary hyperten-
sion was also preliminary terminated due to an 
increased risk of death and other serious adverse 
events in the riociguat-treated group vs placebo 
[298]. In a randomised controlled trial STEP-IPF 
of phosphodiesterase-5 inhibitor, sildenafil, used 
in patients with advanced IPF, defined as TL,CO 
< 35% of predicted, the primary endpoint, i.e. 
a significant increase of distance in the 6MWT, 
was not met [78]. On the other hand, in the sil-
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denafil-treated group a significant improvement 
vs placebo was demonstrated in terms of secon-
dary endpoints, i.e. dyspnoea severity, quality of 
life, blood oxygen saturation and TL,CO. Based on 
this encouraging data, the INSTAGE study was 
conducted in patients with advanced IPF. The 
study analysed the efficacy and safety of ninte-
danib in combination with sildenafil compared 
with nintedanib and placebo [299]. However, no 
significant benefits of combination therapy with 
nintedanib and sildenafil were demonstrated 
compared with nintedanib monotherapy in this 
population of IPF patients. The only treatment 
currently recommended by the European Society 
of Cardiology/European Respiratory Society (ESC/ 
/ERS) for pulmonary hypertension in correlation 
with IPF involves long-term oxygen therapy, tre-
atment of comorbidities and referring the patient 
to a transplant centre if no contraindications are 
present [300].
 
Recommendation 20.
We suggest that agents dedicated to treating 
pulmonary hypertension NOT be used in IPF 
patients. 
Quality of evidence: very poor
Strength of recommendation: conditional
Votes: strongly for (the use of agents dedica-
ted to treating pulmonary hypertension in IPF pa-
tients) — 0; conditionally for — 1; strongly against 
— 3; conditionally against — 13; abstained — 4
Commentary
Coexistence of pulmonary hypertension in 
IPF patients is a well-defined prognosis-worse-
ning factor in this serious disease. A retrospective 
analysis of IPF patients who underwent right he-
art catheterisation as part of pre-lung transplant 
assessments demonstrated higher annual morta-
lity (28% vs 5, 5%) in the group of patients with 
pulmonary hypertension compared with those 
without pulmonary hypertension [294]. Despite 
many clinical randomised trials assessing the 
efficacy of different drug classes used in the tre-
atment of pulmonary hypertension, no beneficial 
effects have been yet demonstrated in the case 
of IPF patients with concomitant pulmonary hy-
pertension. The most encouraging results came 
from the STEP-IPF study (improvement only in 
terms of secondary endpoints), which enrolled 
180 patients with advanced IPF [78]. In addition, 
data from the international COMPERA registry 
confirmed short-term functional improvement in 
certain patients treated with agents dilating pul-
monary vessels, mostly phosphodiesterase-5 inhi-
bitors [301]. Unfortunately, these results have not 
been yet confirmed in large randomised clinical 
trials. Therefore, agents dilating pulmonary ves-
sels are not recommended for routine use in IPF 
patients associated with pulmonary hypertension 
outside of randomised clinical trials. There is an 
ongoing study of sildenafil added to pirfenidone 
treatment (clinicaltrials.gov NCT02951429) in 
patients with probable pulmonary hypertension 
assessed non-invasively [302].
NON-PHARMACOLOGICAL TREATMENT  
AND PALLIATIVE CARE
Question 21. Should pulmonary 
rehabilitation be used in IPF patients?
Introduction
Pulmonary rehabilitation is a complex in-
tervention based on thorough assessment of the 
patient’s condition, adjusted to their individual 
capabilities and involving training, education 
and shaping of appropriate health-promoting 
behaviours. It is aimed at improving the patients’ 
physical and mental fitness and long-term com-
pliance with the aforementioned behaviours 
[303]. The beneficial effect of rehabilitation 
in IPF patients has been documented in many 
prospective, non-randomised observational stu-
dies [304–310] and numerous randomised trials 
[311–318]. A 2014 meta-analysis of 5 randomised 
studies (86 patients with ILDs, including IPF, un-
dergoing rehabilitation and 82 non-rehabilitated 
patients comprising the control group) confirmed 
the beneficial effects of rehabilitation on distan-
ce in the 6MWT, peak oxygen uptake, dyspnoea 
severity and quality of life, with lack of adverse 
effects [319]. The most recent meta-analyses of 
5 randomised trials involving more than 130 IPF 
patients divided into a group of subjects receiving 
rehabilitation and a control group demonstrated 
an improvement in exercise tolerance, reduction 
of symptoms and quality of life improvement 
[320]. Another meta-analysis of 4 randomised 
trials (a total of 142 subjects) confirmed beneficial 
short-term effects of rehabilitation on exercise 
capacity and quality of life but failed to confirm 
any distant effects [321]. The most recent meta-a-
nalysis of 7 studies involving 190 IPF patients de-
monstrated improved exercise capacity measured 
as distance in the 6MWT and improved quality 
of life [322]. Pulmonary rehabilitation involves 
the following: physical exercises (aerobic, endu-
Wojciech J. Piotrowski et al., Diagnosis and treatment of idiopathic pulmonary fibrosis
77www.journals.viamedica.pl
rance and flexibility exercises as well as arm and 
inspiratory muscle training), education (symptom 
management, oxygen therapy optimisation, self-
care), optimisation of nutrition and psychosocial 
support [323]. A rehabilitation programme should 
be started in a specialist pulmonary rehabilitation 
centre, in the inpatient or outpatient setting, 
and led and supervised by adequately prepared 
medical staff [324]. Attempts should be made to 
continue the programme at home. Supervised 
home rehabilitation, with optional use of tele-
medicine, can be an alternative to the traditional 
method [325]. 
Recommendation 21.
We recommend the use of pulmonary reha-
bilitation in IPF patients. 
Quality of evidence: moderate
Strength of recommendation: strong
Votes: strongly for (the use of pulmonary re-
habilitation in IPF patients) — 15; conditionally 
for — 5; strongly against — 0; conditionally aga-
inst — 0; abstained — 1
Commentary
The authors of the international guidelines 
for IPF diagnosis and treatment of 2011 recom-
mend pulmonary rehabilitation in IPF patients 
(weak recommendation, very poor evidence quali-
ty), concluding that rehabilitation should be used 
in most IPF patients, but it may be appropriate 
to forgo it in a minority of them [10]. The update 
of treatment guidelines of 2015 does not pertain 
to pulmonary rehabilitation of IPF patients [75]. 
However, a majority of randomised trials were 
published after 2011 [311–314, 317]. Currently, 
the amount and quality of evidence should be 
considered sufficient to recommend pulmonary 
rehabilitation in IPF patients as an important 
component of treatment. The question of precise 
identification of patients who can benefit most 
from it still needs to be elucidated. Many authors 
stress the validity of initiating rehabilitation in 
an early period of the disease [307, 308], altho-
ugh greater early effects are achieved in patients 
with more advanced disease [313]. Another issue 
is one associated with individualisation and 
standardisation of the rehabilitation programme, 
taking into account the patient’s capabilities and 
preferences and resulting, among others, from the 
degree of functional impairment, need for oxygen 
therapy and comorbidities. Another controversial 
question is that of the duration of the effects of 
rehabilitation, since many authors claim that the 
effects last up to 6 [307, 313, 321], 11 [326] or 
even 12 months [325] after completing the pro-
gramme, while others do not confirm its lasting 
beneficial effects in a longer term [315, 321]. Lack 
of unequivocal data confirming distant effect 
indicates it is necessary to use rehabilitation in 
a continuous and systematic way.
Question 22. Should long-term oxygen 
therapy (LTOT) be used in patients with 
respiratory failure in the course of IPF?
Introduction
Sings of chronic hypoxaemic respiratory 
failure occur in IPF patients at a  late stage of 
the disease. This is when one should consider 
indications for long-term home oxygen thera-
py (LTOT). However, there is no unambiguous 
evidence confirming the efficacy of LTOT in IPF 
patients. The studies conducted to date have only 
demonstrated a shorter survival in oxygen-treated 
patients due to respiratory failure in the course of 
ILD compared with COPD [327]. The cited studies 
were not randomised and contained no compa-
rative groups, so the impact of LTOT on survival 
cannot be directly assessed. Recently published 
qualitative studies point to the fact that some IPF 
patients using LTOT reported improvement [328, 
329]. Others complained about the bothersome-
ness of this type of treatment and the limitations 
in everyday life it causes [329].
 
Recommendation 22.
We recommend using long-term oxygen 
therapy (LTOT) in patients with chronic respi-
ratory failure in the course of IPF. 
Quality of evidence: very poor
Strength of recommendation: strong
Votes: strongly for (the use of long-term 
oxygen therapy in IPF patients with chronic 
respiratory failure) — 15; conditionally for — 5; 
strongly against — 0; conditionally against — 0; 
abstained — 1
Commentary
This recommendation is in line with the 
position presented in the international ATS/
ERS/JRS/ALAT recommendations of 2011 (strong 
recommendation, very poor quality of evidence) 
[10]. There is limited data supporting the benefi-
cial effects of LTOT in patients with respiratory 
failure in the course of IPF, so this recommen-
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dation stems from medical knowledge of the pa-
thophysiology of respiration and the established 
clinical management of respiratory failure. Above 
all, the authors took into account the results of stu-
dies confirming the efficacy of chronic oxygen the-
rapy in patients with other chronic lung diseases, 
including COPD. The recommendation does not 
contradict recommendations in guidelines by wor-
king groups or pulmonology societies published 
after 2011 [87, 330, 331]. The authors of the ATS/
ERS/JRS/ALAT guidelines (2011) failed to specify 
unambiguously the qualification criteria for LTOT, 
leaving this to the treating doctor’s discretion [10]. 
The authors of Swiss [87], Japanese [330] and 
Australian [331] guidelines recommend LTOT in 
IPF patients diagnosed with resting hypoxaemia 
(PaO2 ≤ 55 mm Hg or PaO2 < 60 mm Hg if one of 
the following signs is present: signs of pulmonary 
hypertension, signs of right ventricular hyperto-
phy, polyglobulia). The patient should use oxygen 
for at least 15 hours a day and for the entire night.
Question 23. Should oxygen be used 
during exercise in IPF patients?
Introduction
The course of IPF involves limitation of exerci-
se tolerance with concomitant shortness of breath, 
caused by insufficient amounts of oxygen delive-
red in relation to the demand. Reduced everyday 
physical activity and dyspnoea affect the patient’s 
quality of life and prognosis [332]. Exertional de-
saturation and increased oxygen demand during 
exercise are negative prognostic factors for morta-
lity and disease progression [333–335]. The use of 
oxygen therapy during exercise can reduce dyspno-
ea and improve physical capacity. However, there 
is an insufficient number of studies confirming the 
beneficial effects of oxygen therapy during exercise 
in IPF patients with exertional hypoxaemia. In 
a meta-analysis of three cross-over studies compa-
ring the effects of oxygen and air from a portable 
oxygen source, two studies failed to confirm any 
benefits of oxygen therapy [336]. The third study 
[337] demonstrated improved oxygen saturation 
but with no effect on perceived dyspnoea. Another 
study demonstrated reduced dyspnoea, improved 
capacity and decreased desaturation degree in 
patients receiving oxygen during exercise, with 
high oxygen concentrations in inspiratory air (FiO2 
> 0.50) [338]. In another randomised, cross-over, 
two-week, prospective trial comparing the effects 
of two-week oxygen therapy using a portable oxy-
gen source with a period without oxygen therapy 
in IPF patients with latent hypoxaemic respiratory 
failure, oxygen therapy was found to have a be-
neficial effect on the quality of life [339]. Oxygen 
therapy using a portable oxygen source does not 
reduce exercise-induced increase in pulmonary 
artery pressure [340]. 
Recommendation 23 
We suggest using oxygen during exercise 
in IPF patients with dyspnoea and exertional 
desaturation. 
Quality of evidence: very poor
Strength of recommendation: conditional
Votes: strongly for (the use of oxygen during 
exercise in IPF patients with dyspnoea and exer-
tional desaturation) — 5; conditionally for — 13; 
strongly against — 0; conditionally against — 0; 
abstained — 3
Commentary
According to the authors of the British Tho-
racic Society (BTS) guidelines, oxygen from 
a portable source should not be routinely used in 
patients who do not qualify for home oxygen the-
rapy or those who already receive this treatment 
chronically [341]. It should, however, be recom-
mended to LTOT patients who are still involved in 
outdoor activities as well as patients participating 
in pulmonary rehabilitation programmes if impro-
ved physical capacity has been demonstrated as 
a result of using a portable oxygen source [341]. 
The AmbOx trial results suggest that, compared 
with lack of oxygen therapy, the use of oxygen 
from portable sources during exercise decreases 
desaturation and dyspnoea during exercise and 
also improves the quality of life in patients with 
ILDs, without resting hypoxaemia [339]. When 
recommending the use of oxygen from portable 
sources, one should remember the costs and phy-
sical strain associated with carrying or pulling an 
oxygen-delivering device as well as the need for 
frequent refilling [342]. Therefore, it is necessary 
to perform further studies assessing the efficacy 
of oxygen therapy in patients with exertional 
hypoxaemia. It is recommended to perform an 
individual assessment of potential benefits based 
on objective examinations.
Question 24. Should preventive 
vaccinations be used in IPF patients?
Introduction
The elderly, especially patients with chro-
nic lung diseases, contracting flu or pneumococ-
cal pneumonia, are at a high risk of death. This 
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can be avoided through preventive vaccinations 
[343–345]. The Polish recommendations sug-
gest vaccinating individuals above the age of 
50 against pneumococci, stressing the fact that 
pneumococcal pneumonia in persons additio-
nally affected by chronic lung disease is much 
more frequent, i.e. five times more frequent in 
IPF patients [346]. At the same time, we should 
remember that IPF by definition refers to people 
after the age of 50 and its incidence increases 
with age [4, 5, 347]. In line with the WHO guide-
lines, Poland’s National Flu Centre (Krajowy 
Ośrodek ds. Grypy) recommends flu vaccinations 
in all individuals aged 6 months and more, espe-
cially in populations at the highest risk of flu or 
its serious complications. This group, similarly 
to pneumococcal pneumonia, includes the el-
derly and patients with chronic lung diseases 
[348]. Given the marked antigen variability of 
the influenza virus, every year a new vaccine is 
produced. Its aim is to protect the patient from 
flu and the serious consequences of its possible 
complications in the upcoming epidemiological 
season. 
Recommendation 24.
We recommend use of pneumococcal and 
flu vaccinations in IPF patients. 
Quality of evidence: very poor
Strength of recommendation: strong
Votes: strongly for (the use of protective vacci-
nations in IPF patients) — 13; conditionally for — 6; 
strongly against — 0; conditionally against — 0; 
abstained — 2
Commentary
Patients with IPF are at a  higher risk of 
pneumococcal pneumonia and flu as well as 
serious complications of these diseases. It is 
important to note that IPF patients’ breathing 
reserves are limited to varying degrees. In indi-
viduals with a markedly lowered FVC and/or si-
gnificantly impaired carbon monoxide diffusion 
indicated by TL,CO, a sudden further worsening 
of these parameters caused by bacterial or viral 
pneumonia can lead to acute respiratory failure 
necessitating invasive mechanical ventilation or 
even a life-threatening condition. Additionally, 
respiratory infection can be a  factor causing 
an AE-IPF [349–351], according to the current 
definition of this condition [38]. It is associated 
with high mortality and can occur at any stage of 
the disease, even in asymptomatic patients who 
only have radiographic changes [210, 352]. In-
fection prevention should all the more comprise 
an important element of managing IPF patients. 
According to the current guidelines by the Cen-
ters for Disease Control and Prevention (CDC) 
[353] and Polish expert recommendations by the 
Polish Nationwide Flu Prevention Programme 
(Ogólnopolski Program Zwalczania Grypy) on 
flu prophylaxis [354], flu vaccination should 
be performed once a year, while a conjugated 
PVC13 vaccine against pneumococci requires 
a single administration. It is recommended to 
perform an additional pneumococcal vaccina-
tion with a polysaccharide PPSV23 vaccine after 
one year [353].
Question 25. Should patients with 
advanced IPF be referred to palliative 
care centres?
Introduction
The main objective of palliative care is to 
achieve the best possible quality of life in pa-
tients whose disease is not effectively treated 
with causal treatment [355, 356]. One of such 
diseases is IPF. As demonstrated by studies as-
sessing the use of pirfenidone or nintedanib in 
IPF treatment, a specific therapy can slow down 
the course of the disease, but it reduces clinical 
symptoms only to a small extent [81, 83]. These 
symptoms (dyspnoea, cough, anxiety, depression, 
chronic fatigue) can at the same time affect the 
quality of life irrespective of the degree of disease 
advancement [357]. In addition to alleviating 
the somatic complaints as well as mental and 
spiritual suffering, comprehensive palliative care 
activities include also good communication with 
the patient and their family, help in solving social 
problems, affirmation of life with accepting death 
as a natural process, constant care until death 
and caution taken not to prolong the passing 
persistently. The international ATS/ERS/JRS/
ALAT guidelines for the treatment of IPF patients 
explicitly recommend palliative care targeted at 
symptoms (palliation) as a mandatory component, 
complementary to specific (antifibrotic) treatment 
targeted at the underlying disease [10]. Such care 
should be offered to the patient at least from the 
moment the disease enters the advanced stage or 
the first life-threatening exacerbation occurs [331, 
358, 359]. In advanced and terminal IPF stages 
patient care should be provided by trained mul-
tidisciplinary teams of home and inpatient care. 
It is believed that the best form of palliative care 
in this period is home care. 
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Recommendation 25.
We suggest that patients with advanced IPF 
be referred to palliative care centres. 
Quality of evidence: very poor
Strength of recommendation: conditional
Votes: strongly for (referring patients with 
advanced IPF to palliative care centres) — 9; 
conditionally for — 9; strongly against — 0; con-
ditionally against — 0; abstained — 3
Commentary
Idiopathic pulmonary fibrosis patients, espe-
cially with advanced disease, can suffer from 
difficult-to-treat symptoms, such as dyspnoea, 
cough, fatigue or anxiety [360]. These symptoms 
significantly reduce the quality of life, irrespective 
of objective physiological parameters of the disease 
advancement. At the same time, patients experience 
a lot of spiritual suffering, being aware of the pro-
gression of the incurable disease and inevitability 
of death. Improvement of patients’ quality of life 
at this stage can be best provided in a compre-
hensive way by specialist palliative care centres. 
Although no direct medical evidence is present 
(EBM, evidence-based medicine) supporting the 
benefits of palliative treatment in IPF, it is indirectly 
provided by extrapolation of results from studies of 
other advanced chronic lung diseases [361, 362]. 
However, compared for instance with lung cancer 
patients, IPF patients have limited access to pal-
liative care [363]. It needs to be emphasised that 
care offered by palliative care centres should be 
individualised — adjusted to the patient’s as well 
as caregivers’ needs [10]. At present, palliative care 
options in the context of IPF patient care in Poland 
are severely limited. This is caused, above all, by an 
insufficient number of centres and lack of nursing 
personnel dedicated to caring for patients with ILDs.
Question 26. Should morphine be used in 
palliative treatment?
Introduction
Dyspnoea is a defensive mechanism leading 
to increased ventilation and improved respira-
tory gas exchange. It is also the most important 
symptom contributing to a poor quality of life in 
IPF patients [364]. Opioids have been demonstra-
ted to decrease shortness of breath significantly 
in patients with chronic respiratory diseases, 
including IPF. They improve breathing comfort, 
exert anxiolytic action by decreasing the level of 
dyspnoea-associated anxiety and have a positive 
effect on sleep quality. The opioid of choice in the 
treatment of dyspnoea in patients with respiratory 
diseases is oral morphine, initially administered 
in an immediate-release form and, after the opti-
mum daily dose has been established, also in 
a controlled-release form [365–370]. However, 
there is no unequivocal evidence for the efficacy 
of morphine inhaled from a nebuliser, despite 
hypothetical benefits of morphine acting on the 
peripheral receptors and lack of systemic adverse 
effects with this mode of administration [371].
Recommendation 26.
We suggest using oral morphine in patients 
with severe IPF in palliative treatment of per-
sisting dyspnoea. 
Quality of evidence: very poor
Strength of recommendation: conditional
Votes: strongly for (the use of morphine in 
patients with severe IPF) — 6; conditionally 
for — 11; strongly against — 0; conditionally 
against — 0; abstained — 4
Commentary
Morphine dosage should be decided on an 
individual basis, discussed with the patient and 
their family and strictly monitored. It is important 
to note that elderly, emaciated or benzodiazepi-
ne-treated patients or those with concomitant 
COPD are more susceptible to opioid action, and 
administration of morphine in patients with hy-
percapnia is associated with a risk of respiratory 
centre depression. The starting oral morphine 
dose of 2.5 mg, administered as frequently as 
every 4 hours, can be safely used in IPF patients 
and gradually increased every couple of days until 
optimum effects are achieved [372]. This appro-
ach to morphine dose titration until reaching the 
optimum daily dose, even one exceeding 30 mg, is 
not associated with sedative effects or respiratory 
depression [373]. There is, however, a possibility 
of a significant problem in the form of constipa-
tion during opioid treatment. Therefore, it is im-
portant to administer laxative or stool-loosening 
agents, such as senna or lactulose [374].
Question 27. Should invasive ventilation 
be used in IPF patients with acute 
respiratory failure?
Introduction
AE-IPF is defined as clinically relevant wor-
sening of respiration characterised by the pre-
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sence of new extensive changes in the alveoli in 
a patient with an existing or new IPF diagnosis. 
This deterioration cannot be explained by circu-
latory failure or overhydration and is characteri-
sed by unexplained dyspnoea (exacerbation or de 
novo), typically lasting for < 1 month [38]. There 
are no unequivocal recommendations for effecti-
ve management both in the case of a known cau-
se and an acute exacerbation in an IPF patients 
if the event is associated with life-threatening 
hypoxaemia. The choice of therapeutic methods 
is limited to invasive ventilation, non-invasive 
ventilation (NIV) support, extracorporeal mem-
brane oxygenation (ECMO) or administration 
of oxygen through a high-flow nasal cannula 
(HFNC) [375]. Idiopatic pulmonary fibrosis 
patients admitted to intensive care units due to 
acute respiratory failure who require mechanical 
ventilation are burdened with a poor prognosis 
and high mortality [376]. In these patients no 
improvement has been demonstrated in terms 
of survival or distant prognosis. Therefore, it 
is generally recommended to avoid this type of 
treatment in IPF patients, except for a situation 
where it is possible to perform lung transplant 
in a short time (bridge therapy) [377].
 
Recommendation 27 
We suggest that invasive ventilation NOT be 
used in IPF patients with acute respiratory failure. 
Quality of evidence: poor
Strength of recommendation: conditional
Votes: strongly for (the use of invasive venti-
lation in IPF patients) — 0; conditionally for — 0; 
strongly against — 6; conditionally against — 12; 
abstained — 3
Commentary
An alternative to mechanical ventilation 
can be non-invasive ventilation (NIV). In a re-
trospective study by Vianello et al., NIV use 
was associated in selected IPF patients with 
clinical benefits, such as longer survival and 
decreased rate of complications, including 
death [378]. Similarly, Gungor et al. [379] 
demonstrated that the use of NIV in IPF and 
other ILDs is associated with a better overall 
prognosis, although a higher mortality rate was 
observed in patients requiring continuous NIV 
use. Retrospective studies indicate higher mor-
tality in patients who have undergone invasive 
ventilation compared with those treated with 
NIV [380, 381]. 
Question 28. Should IPF patients be 
referred to lung transplant centres and if 
so, when?
Introduction
The use of antifibrotic agents can slow down 
lung function decline. However, irrespective of 
whether such a  treatment is used, the natural 
history of this disease inevitably leads to the 
development of respiratory failure, secondary 
pulmonary hypertension and death. Furthermore, 
this prognosis is worsened by coexistence of other 
chronic diseases, especially cardiovascular, and 
the presence of AE-IPF. If all suggested methods 
of both non-pharmacological and pharmacological 
treatment have been attempted, the only possible 
form of therapeutic management that could po-
tentially improve the quality of life and prolong 
survival is lung transplant. The consensus report 
of the International Society for Heart and Lung 
Transplantation (ISHLT) specifies potential can-
didates for lung transplant as adult patients with 
a chronic lung disease in its end stage who additio-
nally have a high risk of death within two years if 
no transplant is performed and, at the same time, 
are characterised by a high probability of survi-
val after the procedure [382]. An important and 
beneficial global trend is the observed continuous 
increase in the number of lung transplant proce-
dures [383]. IPF holds an important place among 
indications for lung transplant. On the other hand, 
considering the unfavourable prognosis associated 
with IPF (median survival of 2–3 years since dia-
gnosis and 20–30% 5-year survival [10]) as well 
as lack of both causal treatments and therapies 
that would significantly modify survival, lung 
transplant will still hold an important place in the 
therapeutic strategy of this disease. It is also worth 
noting that since the Lung Allocation Score (LAS) 
was introduced in the US, pulmonary fibrosis has 
overtaken COPD as the main transplant category 
as regards the relative priority assigned for the 
distribution of lungs available for transplantation. 
Recommendation 28A 
We recommend referring to lung transplant 
centres all IPF patients without contraindica-
tions for the procedure. 
Quality of evidence: poor
Strength of recommendation: strong
Votes: strongly for (referring all IPF patients 
without contraindications for lung transplant to 
transplant centres) — 14; conditionally for — 5; 
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strongly against — 0; conditionally against — 1; 
abstained — 1
Commentary
Given the fact that IPF is a progressive di-
sease, irrespective of whether antifibrotic treat-
ment is started, we can assume that referring all 
IPF patients to lung transplant centres is a valid 
approach unless they have contraindications 
for the procedure. The validity of performing 
lung transplants in patients with lung fibrosis is 
supported by literature data. However, the evi-
dence is associated with significant limitations, 
mainly the retrospective design of studies or 
heterogeneity of groups caused by enrolment 
of patients with lung fibrosis forms other than 
IPF. In a single-centre study of 46 IPF patients, 
Thabut et al. reported a survival rate of 79.4% in 
the first, 63.5% in the second and 39% in the fifth 
year following lung transplant. A multivariate 
analysis revealed, after adjusting for potential 
confounding variables, that lung transplant re-
duced the risk of death by 75% (95% CI: 8–86%; 
p = 0,03). Median organ wait time in this study 
was 51 days [384]. Other trials report a five-year 
survival of as much as 50–56% [385, 386]. These 
include a study by Keating et al., who demon-
strated a more favourable long-term prognosis 
in IPF compared with other indications for lung 
transplant. Despite a  clear tendency towards 
a higher number of bilateral transplants [383], the 
question of whether one or both lungs should be 
routinely transplanted in IPF remains open. The 
results of studies analysing the benefits and risks 
of both procedures are varied [387–398] and make 
it impossible to adopt an unambiguous position. 
Therefore, this decision needs to be taken on an 
individual basis for each patient. In addition, it 
should be noted that unilateral transplantation 
is associated with an undoubted benefit in terms 
of managing organs for transplantation and that 
bilateral transplant is associated with a  longer 
wait time [391]. 
Recommendation 28B 
We suggest referring IPF patients to lung 
transplant centres immediately after the disease 
is diagnosed. 
Quality of evidence: very poor
Strength of recommendation: conditional
Votes: strongly for (referring IPF patients to 
transplant centres immediately after diagnosis) — 
7; conditionally for — 12; strongly against — 0; 
conditionally against — 0; abstained — 2
Commentary
The times of referral and inclusion in the wait-
list are clearly specified in the ISHLT consensus 
[382]. Patients should be referred to a transplant 
centre when at least one of the following criteria 
is met: 
1. A histopathological or radiographic pattern 
warranting the diagnosis of UIP or fibrotic 
NSIP, irrespective of lung function.
2. Lung function impairment: FVC < 80% of 
predicted or TL,CO < 40% of predicted.
3. Any dyspnoea or functional limitation asso-
ciated with lung disease.
4. Any requirement of oxygen, including situ-
ations when oxygen is needed only during 
exercise.
5. For ILD, inability to improve dyspnoea, oxy-
gen demand and/or lung function after causal 
treatment.
On the other hand, including a patient in the 
waitlist is recommended when at least one of the 
following criteria is met:
1. An FVC decline ≥  10% during a 6-month 
follow-up (a decline of 5% is also associated 
with a poorer prognosis and can be a basis 
to include in the list).
2. A decline in TL,CO > 15% within 6 months of 
follow-up.
3. Desaturation < 88% or distance < 250 m in 
the 6MWT or a decline in distance > 50 m 
in the 6MWT during 6 months of follow-up.
4. Pulmonary hypertension diagnosed based on 
heart catheterisation or 2D echocardiography.
5. Hospitalisation due to impairment of respira-
tory parameters, pneumothorax or disease 
exacerbation
It is clear from these recommendations that 
the mere diagnosis of the UIP pattern is an in-
dication for referral to a lung transplant centre. 
In addition, the validity of early referrals of 
patients to such a centre is supported by litera-
ture data which indicate higher mortality in IPF 
patients waiting for transplantation [384, 391]. 
The position that patients should be referred to 
transplant centres is also in line with the current 
ATS/ERS/JRS/ALAT guidelines [29].
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